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ABSTRACT 
 
Adaptation of bacteria to their environment is a necessity to keep their fitness 
and survival under limiting conditions. In chapter I of this work we demonstrated 
that adaptation of glycopeptide-resistant S. aureus (GISA) happens at the cost of 
resistance loss. An in vitro generated step selected teicoplanin-resistant mutant 
was phenotypically and genotypically characterized and compared to its 
glycopeptide-susceptible parent S. aureus strain SA113, prior to and after 
challenging the host in a foreign body infection model. Slower growth, increased 
thickness of the bacterial cell wall, increased N-acetylglucosamine incorporation, 
decreased hemolysis, and downregulation of some virulence-associated genes 
were determined upon in vitro step selection. In vivo host pressure together with 
the absence of antibiotics were shown to impair this GISA phenotype and to 
result in the selection of fitter variants at the cost of resistance loss. 
 
In a further study we compared the virulence and pathogenicity of isolates of two 
epidemic ST8 and ST5 health-care associated methicillin-resistant S. aureus 
(MRSA) clones with MSSA isolates of variable STs that are prevalent in French 
clinical settings and with MSSA of the same ST in a murine sepsis model. 
Mouse mortality, induced by the different groups of MRSA ST8 and ST5 and 
MSSA ST8, ST5 and var. ST was related to phenotypic and genotypic features. 
MRSA isolates of both clones ST8 and ST5 caused higher mortality than MSSA 
expressing var. ST. However, higher mortality was not related to the presence of 
SCCmec, since only ST5 but not ST8 isolates showed a higher virulence in the 
presence of this resistance determinant. Despite the same genetic background 
individual clonal MRSA isolates had heterogeneous virulence properties. No 
specific virulence factor determined in vitro, was found related to mortality in 
mice. In conclusion, in a bacteraemic model, lethality varied with the sequence 
type, and was modulated by SCCmec. Within the same ST, clonality was not 
associated with a homogenous outcome in the murine sepsis model. 
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Whole genome sequencing of clonal lethal and non-lethal isolates will allow 
identifying virulence factors relevant to the outcome in this model.  
 
In the third part of this thesis we investigated phenotypic properties of the clonal 
MRSA ST8 isolates that had a variable outcome in the murine sepsis model and 
measured innate and adaptive immune responses of 7 lethal and 3 non-lethal 
isolates. Clonality of the 10 MRSA ST8 isolates was certified by MLVA. In vitro 
assays, simulating steps that occur during the course of infection were performed 
in order to detect host response discriminating differences between lethal and 
non-lethal isolates. While chemotaxis, bactericidal activity and apoptosis of PMN 
were similar for lethal and non-lethal isolates, a preliminary study yielded a 
different specific immune response induced by a lethal compared to a non-lethal 
isolate.  
The role of the adaptive immunity in the outcome of an infection with lethal and 
non-lethal isolates will be investigated in further.  
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AIM OF THE STUDY 
 
Since the introduction of the first !-lactam Penicillin in 1944, the emergence and 
development of antibiotic resistance in Staphylococcus aureus has become a 
severe problem. Antibiotic resistance of this gram-positive bacterium is a 
particular threat due to its multiple virulence factors, its immune evasion 
mechanisms and its great adaptive power to antimicrobial agents. The aim of this 
thesis was to address the impact of glycopeptide and methicillin resistance on 
S. aureus, and to evaluate the role of resistance and the role of host factors on 
its virulence during an infection.  
Glycopeptide intermediate S. aureus (GISA) resistance arises as a result of 
multiple mutations and alterations in gene expression and is associated with 
phenotypic alterations, which are a fitness burden for the pathogen. However not 
all GISA isolates are bearing the same alterations, and the resistance-
mechanisms underlying this resistance type are still not well understood. Since 
stability of the resistance phenotype, fitness of GISA strains, and the impact of 
the host in the absence of antibiotics is unknown in vivo, we aimed studying the 
resistance phenotype prior to and after an infection in the absence of antibiotics 
in a well defined murine infection model (Chapter I).  
With the acquisition of the SCCmec element S. aureus became one of the most 
frequent pathogens responsible for hospital-acquired infections. Most MRSA 
strains belong to six clonal complexes (CC) that are disseminated worldwide. 
Patient studies aiming at evaluating differences in pathogenicity and virulence 
between MRSA and MSSA isolates are impaired by multiple confounding factors; 
they do not allow the analysis of virulence that is associated with methicillin-
resistance. Furthermore, in most patient studies genetic analysis of infectious 
strains is missing. To eliminate host-associated confounding factors we choose 
to study the virulence of two epidemic MRSA clones predominating in France in a 
controlled murine sepsis model. Furthermore by precise molecular 
characterization of the isolates we aimed assessing the role of factors 
responsible for virulence and for a successful dissemination (Chapter II).  
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The outcome of an infection is defined by parameters of both the host and the 
pathogen. We found a variable virulence among MRSA isolates belonging to the 
same clone, which was not attributable to any of the measured toxins or 
adhesins. As we postulated that lethal and non-lethal MRSA isolates would elicit 
a differing immune response, we investigated innate and adaptive host response 
to the clonal isolates in vitro and ex vivo. This might allow us to conclude back on 
factors differing between the isolates (Chapter III).  
All projects were focused on the consequence of antibiotic resistance upon 
virulence in murine infection models. The results revealed a) that glycopeptide 
resistance was unstable in vivo and imposed a fitness burden b) that in a 
systemic infection SCCmec variably affected virulence of S. aureus depnding on 
the clonal background, and c) that within clonal isolates unknown factors 
modulate virulence.  
 
 
7 
GENERAL INTRODUCTION 
 
Staphylococcus aureus 
Staphylococcus aureus (S. aureus) is a 1!m gram-positive bacterium with a 
circular chromosome, growing in grape-like clusters and belonging to the family 
of Micrococcaceae. The S. aureus genome ranges in the size from 2.8 - 2.9 Mb 
and is composed of a core genome and an accessory genome. The core 
genome is making up approximately 75% and is highly conserved among 
isolates. The accessory genome represents approximately 25% and consists of 
mobile genetic elements, like bacteriophages, pathogenicity islands, plasmids 
and transposons, which often carry genes conferring virulence or resistance (33). 
The multitude of virulence factors combined with the great adaptive power to 
evolve and acquire resistance mechanisms declares S. aureus to one of the 
major human pathogens, causing both healthcare and community-acquired 
infections. Infections caused by this pathogen can be localized, e.g. soft tissue 
infections and abscesses, toxin- related, e.g. food poisoning and toxic shock 
syndrome, or systemic and life threatening, e.g. endocarditis and sepsis (55). 
S. aureus is colonizing nose and throat of 20% of the human population 
persistently, 60% are intermittently colonized, while 20% never carry this 
pathogen (28). Nasal carriers of S. aureus bear an increased risk to become 
septic, once bacteria gain access to the bloodstream due to breaches in the 
nasopharyngeal or other mucosal colonized niches. Interestingly, mortality rate 
from sepsis among carriers is significantly lower compared to non-carriers (60, 
63, 64). Colonization and adhesion to host cells are not only the critical events 
before invasion and subsequent infection of the host, but also the driving force 
for a successful inter-human dissemination. During the exponential growth 
phase, S. aureus is regulating colonization and dissemination by expressing 
surface molecules, which are important for adhesion, while during the stationary 
phase secretion of toxins and enzymes enable tissue disruption and thus 
invasion (34).  
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The cell wall of S. aureus is one of the major targets of antibiotics. Since the 
thesis focuses on cell active antibiotics and resistance against them the cell wall 
is described in depth. Fifty percent of its cell wall is composed of peptidoglycan 
(PGN), a large polymer consisting of alternating N-acetylglucosamine (GlcNAc) 
and N-acetylmuramic acid (MurNAc), which form a dissacharide subunit. The 
MurNAc subunit carries a stem peptide composed of L-Ala– D-Gln- L-Lys- D-Ala- 
D-Ala. The sugar subunits are linked together by 1,4-! linkages forming glycan 
strands, which are in turn crosslinked by pentaglycin brigdes between the L-Lys 
in the 3rd position of the one stem peptide and the D-Ala in the 4th position of the 
neighboring stem peptide. Most clinical S. aureus isolates are encapsulated 
expressing either capsule type 5 or 8, which have anti-phagocytic functions (32). 
Several groups were able to demonstrate that the cell wall of S. aureus is not 
only a biochemical structure that is essential to withstand the cytoplasmic turgor 
pressure. The composition of PGN, teichoic acids (TA), and lipoproteins (LP) are 
main stimuli of host-response via TLR2 and Nod2 (52, 56).   
 
Antibiotic resistance in S. aureus 
S. aureus has a great adaptive power to antimicrobial agents and this represents 
a severe problem in infections since there exist meanwhile resistances to all 
antibiotics, which are available in clinical practice (61). Target pathways of 
antibiotics are cell wall biosynthesis, transcription, DNA replication, protein 
synthesis, and biosynthesis of essential-small molecules. Resistance 
mechanisms are based on one of three strategies: 
a) Inactivating the antibiotic.  
b) Preventing the antibiotic from reaching the target.  
c) Altering the target to render it insensitive to the drug.  
These survival strategies are mediated in general either by mutation of a gene or 
by acquisition of genetic material carrying resistance determinants. A 
spontaneous mutation frequency of 10-8 enables the emergence of resistant 
mutants within the host, even before the first confrontation with the drug takes 
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place. Thus, once starting treatment with antibiotics, those mutators have a 
certain advantage to cope with antibiotic pressure (7). The genetic changes may 
often impair original functions of genes or gene subsets resulting in a fitness 
cost, which is described as reduced replication rate, decreased survival, reduced 
transmission rate and reduced virulence (4). However, since natural and clinical 
environments select for fitter variants, bacteria respond either with reversion of 
the mutation resulting in the loss of resistance or with a compensation by 
secondary mutations allowing maintenance of the resistance and with that the 
fitness (42).  
Further factors contributing to resistance against antibiotics are e.g. the formation 
of biofilm or small colony variants (SCV), mechanisms usually used to protect 
bacteria from the host defense. The resistance of bacteria within a biofilm is not 
due to genetic mechanisms as known for their planktonic counterparts, but due to 
several characteristics of the biofilm itself: e.g. i) the extracellular matrix, which is 
limiting the diffusion of certain drugs; ii) the waste accumulation and alteration of 
the microenvironment due to high bacterial density compromising the 
antimicrobial action; iii) the upregulation of certain destroying enzymes like beta-
lactamases; iv) the alteration of growth behavior and v) the development of 
persister cells, which are not affected by antibiotics, since these drugs act only 
on growing cells (14, 53). Bacteria further escape of the host response 
mechanisms by residing within host cells thereby forming often SCVs. They are 
characterized by a low membrane potential, which makes them resistant to all 
antibiotics (5).  
The development of antibiotic resistance is promoted by the fact that bacteria 
occur in high numbers, possess a short generation time, and efficient 
mechanisms for gene exchange, which is additionally favored by the widespread 
and sometimes inappropriate use of antimicrobial agents (7, 54).  
Whenever a new class of antibiotics was introduced onto the market sooner or 
later resistance against the present drug emerged. Since the introduction of the 
first antibiotic penicillin more than 60 years ago, there is competition between 
drug development and the emergence of new resistance mechanisms. 
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Meanwhile, 12 classes of antibiotics composed of several subgroups were 
introduced, each acting on a different target of the bacterial cell, trying to combat 
with resistant strains, each being successful for a certain time but, nevertheless 
being overcome by new resistance mechanisms acquired or developed by the 
pathogen. Resistances emerged against all of them: beta-lactams and 
glycopeptides acting on the cell wall biosynthesis; fluoroquinolones targeting the 
DNA replication and DNA repair mechanisms; aminoglycosides, tetracyclines, 
chloramphenicol, macrolides-lincosamides-streptogramin B (MLS), fusidic acid, 
sulfonamides, trimethoprim, and mupirocin inhibiting protein synthesis.  
In the history of antibiotics, the most useful agents treating staphylococcal 
infections have been the beta-lactam antibiotics with penicillin as prototype. The 
mode of action of penicillin is explained by the structural resemblance between 
the drug and the natural substrate of the transpeptidases. Binding of the beta 
lactam moiety instead of the PGN precursor to the transpeptidases weakens the 
crosslinking of the cell wall and results in cell death. The occurrence of uniformly 
beta-lactam resistant strains, i.e. strains producing beta-lactamases and thus 
destroying the beta-lactam ring, led to the development of further semi-synthetic 
beta-lactams and other classes of antibiotics. However the irresistible resistance 
development awarded glycopeptide antibiotics the prominent role of being the 
last choice of an effective agent. 
 
Resistance to beta-lactam antibiotics 
Staphylococcal resistance against beta-lactam antibiotics is based either on the 
production of penicillinases or on the production of a novel penicillin-binding 
protein 2a (PBP2a), which are both key-players in the cell wall synthesis in the 
presence of beta-lactam antibiotics.  
 
Penicillin resistance 
Only two years after the introduction of penicillin in the early 1940s, the first 
penicillin-resistant strains were already detected. Today more than 90% of 
clinical isolates of S. aureus are resistant. Resistance to penicillin is provided by 
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the penicillinase beta-lactamase. This predominantly extracellular enzyme acts 
on penicillins by disrupting the beta-lactam ring, which is a common structural 
feature of this antibiotic class. The transcription of beta-lactamase is tightly 
regulated by blaZ and its adjacent regulatory genes blaR1-blaI, which are all 
located on a large plasmid. Upon exposure of staphylococci to beta-lactam 
antibiotics the transmembrane beta-lactam sensing protein BlaR1 is 
autocatalytically cleaved. The cleaved BlaR1 in turn cleaves BlaI the repressor 
protein of blaZ and blaR1-blaI. The inactivation of BlaI and its release from the 
operator region allows the transcription of blaZ and its adjacent regulatory genes, 
resulting in the production of beta-lactamase (27). (Fig.1A) 
 
Methicillin resistance 
Methicillin was the first penicillinase-resistant semi-synthetic penicillin introduced 
into the market in 1960 to treat penicillinase-producing S. aureus. 
Already one year later, the first methicillin-resistant S. aureus (MRSA) was 
isolated. Meanwhile, MRSA is responsible for outbreaks of nosocomial S. aureus 
infections and causes also community-acquired staphylococcal infections mainly 
occurring in USA. Resistance to this drug results from the acquisition of the 
staphylococcal chromosome cassette (SCCmec), a chromosomally integrated 
mobile genetic element composed of two essential gene complexes; the mec 
gene complex harboring mecA, a 2 kb gene encoding for the additional 78 kDa 
PBP2a, which has a low affinity to beta-lactams, and the ccr gene complex, 
harboring ccrA and ccrB encoding recombinases, which are responsible for the 
site-specific integration and excision of the entire SCCmec. The integration 
occurs at the bacterial chromosomal attachment site (attBSCC), which is 
downstream of orfX, an open reading frame of unknown function near the origin 
of replication. orfX is well conserved among clinical strains, being present in both 
MRSA and MSSA (26). The origin of the mec-element is not clear, but since 
there is more than 80% homology to a mec-like gene present in S. sciuri, an 
evolutionary relation is likely. However, the native S. sciuri mecA gene does not 
confer methicillin resistance (11).  
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Five different types of this cassette (SCCmec I-V) have been defined by the 
specific combination of the ccr and the mec gene complex. The remaining part of 
the SCCmec complex is designated Junkyard region (J-region), which carries 
nonessential components of SCCmec. Based on differences in the J-region 
SCCmec IV is divided in SCCmec IVa, IVb and IVc. While SCCmec type I, IV 
and V do not carry any further resistance genes to antibiotics except mecA, 
SCCmec type II and type III MRSA do carry additional resistance determinants 
and therefore are also known as multi-resistant-methicillin-resistant S. aureus. 
Multi-resistant strains represent a huge problem in terms of infections to treat 
(23). PBPs are grouped in class A and class B PBPs that are responsible for the 
polymerization of the GlcNAc-MurNAc chains (transglycosylation) and the 
crosslinking of the stem peptides (transpeptidation). Class A PBPs are 
bifunctional and catalyze both transglycosylation and transpeptidation in cell wall 
biosynthesis, whereas class B PBPs are monofunctional and have only 
transpeptidase activity (22). In the presence of antibiotics, the four native 
staphylococcal PBPs get acylated and inactivated in their transpeptidation 
function. Due to its low affinity to beta-lactam antibiotics PBP2a takes over the 
function of the other 4 PBPs in the presence of beta-lactams. However, as 
belonging to class B PBPs thus having only transpeptidase activity, PBP2a uses 
the still active transglysolation site of the native PBP2, a class A PBP, and 
enables cell wall synthesis (46). 
The resistance regulation is similar to that of blaZ. The transmembrane protein 
MecR1 functions as a beta-lactam sensor and is autocatalytically cleaved upon 
exposure to beta-lactams. Subsequently, the inhibitor MecI gets inactivated, 
which in turn enables the transcription of mecA and thus the synthesis of PBP2a.  
Due to a sequence homology of mecI-mecR1 with blaI-blaR1, mecA is under 
dual control. The repressors MecI and BlaI are interchangeable, so that BlaI can 
also repress mecA. (Fig. 1B) 
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Figure 1: Resistance regulation to beta-lactam antibiotics 
Exposure to beta-lactam antibiotics leads to the autocatalytic cleavage of the 
transmembrane sensor protein BlaR1/MecR1 and to the subsequent inactivation 
of DNA binding protein BlaI/MecI. This results either in induction of beta-
lactamase synthesis (A) or induction of PBP2a synthesis (B). 
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Resistance to glycopeptide antibiotics 
Vancomycin, the first glycopeptide antibiotic, was introduced into clinical practice 
in the 1950s, after it was discovered as a second metabolite of the soil bacterium 
Streptomyces orientalis. Despite its efficacy in gram-positive infections, its use 
remained limited because of the low purity of the first lots of vancomycin, and the 
introduction of second and third generation beta-lactams like methicillin. 
However, with the increasing emergence of multiresistant MRSA glycopeptide 
antibiotics became the last resort for treatment of infections. 
Teicoplanin, another important member of the glycopeptide family, extracted from 
Actinoplanes teichomyceticus came onto the market 30 years after the 
introduction of vancomycin and is still available for clinical use in Europe only. 
Even with the development of semi-synthetic derivatives, vancomycin and 
teicoplanin are still the most commonly used drugs for treatment of serious 
infections caused by MRSA.  
Glycopeptide antibiotics act by inhibiting the extracellular steps of the 
peptidoglycan (PGN) biosynthesis of the cell wall. During the cell wall formation 
PGN precursor molecules are translocated from the cytoplasm to the 
extracellular face of the cytoplasmic membrane. At the outer face they are 
immediately polymerized by transglycosylases to build long glycan strands and in 
further steps crosslinked by transpeptidases to build a dense network. 
Glycopeptides inhibit the cell wall reticulation by building a non-covalent complex 
via five hydrogen bonds with the free D-Ala-D-Ala dipeptides of the uncross-
linked PGN pentapeptides. This complex formation prohibits further 
transpeptidation and transglycosylation steps by steric hindrance, where the 
responsible enzymes cannot interact appropriately with their substrates. The 
result is a loose and weakened cell wall leading to the death of the bacterium 
(47).  
Some glycopeptides, e.g. vancomycin, enhance their affinity and with that their 
bactericidal activity to PGN components by forming homodimers. Others, like 
teicoplanin, in turn enhance their bactericidal activity by anchoring into the 
membrane via a fatty acid moiety, which facilitates capturing the precursor 
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molecule right at the site of reticulation (6). Glycopeptides are large and need 
direct access to their target. Therefore, glycopeptides act specifically on gram-
positive bacteria that have a surface exposed and thus easily accessible PGN. In 
contrast, gram-negative bacteria have PGN covered with an outer 
lipopolysaccharide layer, that renders them insensitive to these antibiotics. The 
first resistance against vancomycin was described in Enterococcus faecium in 
1986, wherefrom the term vancomycin-resistant Enterococcus (VRE) (31) is 
derived. The resistance results from an alteration of the drug target, where the D-
Ala-D-Ala dipeptides are replaced by D-Ala-D-Lac or D-Ala-D-Ser (21). As 
described before, the complex formation between drug and the PGN precursor 
molecule is formed via five hydrogen bonds. Since one of the hydrogen bond 
donors is the amide hydrogen in the D-Ala-D-Ala dipeptide, the replacement of 
the terminal D-Ala with D-Lac leads to a 1000-fold decrease in binding affinity. 
The replacement with D-Ser does not suppress hydrogen bonds but induces 
conformational changes, thereby reducing the affinity of the drug slightly (8, 21). 
The so-called van genes, which are located on the transposable element 
Tn1546, are responsible for the alterations in the PGN structure. Six phenotypes 
(vanA-vanG) are known, each consisting of a group of genes contributing to 
resistance. The vanA gene cluster was the first being described and consists of 
a) vanR and vanS, encoding a two-component regulatory system (3), b) vanH 
encoding an alpha-keto acid reductase that generates the D-isomer of lactate (2, 
8), c) vanA encoding an altered D-Ala-D-Ala ligase, which generates the 
despipeptide D-Ala-D-Lact (8), d) vanX encoding a metallodipeptidase that 
degrades D-Ala-D-Ala (48), e) vanY encoding a D,D-carboxypeptidase that 
removes D-Ala from growing PGN precursor molecules (67), and f) vanZ 
encoding a protein that seems to play a role in teicoplanin resistance (1) (Fig. 2A 
+ B). The expression of the resistance genes is tightly regulated by the two-
component regulatory system VanR/VanS. In the presence of glycopeptides, the 
membrane bound sensor His-kinase VanS and the response regulator VanR, 
which are located upstream from vanH, upregulate the expression of the vanHAX 
and vanYZ genes. The autophosphorylation of VanS leads to the phosphoryl 
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transfer to VanR, which in turn binds to the promoter region of vanH and induces 
the transcription of the vanHAX genes. In the absence of glycopeptides, VanS 
dephosphorylates VanR and thus controls gene expression (3).  
Resistance in S. aureus towards glycopeptides emerged later compared to 
Enterococci. 1992 Noble et al. demonstrated for the first time that van resistance 
from Enterococcus faecalis was transferable to S. aureus by conjugation in vitro 
(43). While the first teicoplanin-resistant Enterococcus strain was already 
described in 1990, the first S. aureus strain, which showed an elevated level 
towards vancomycin, was isolated in Japan from a patient with a MRSA infection 
treated with vancomycin in 1996. But this first resistance was not due to the van 
resistance genes, as it was known from Enterococci and thus was classified as 
glycopeptide intermediate S. aureus (GISA). In 2002 the first highly glycopeptide-
resistant S. aureus (GRSA) with a van-resistance mechanism acquired from 
Enterococci outside the laboratories, was isolated from a patient, who had a co-
infection with MRSA and E. faecalis (9). Since S. aureus is a more virulent 
pathogen than E. faecalis, the resistance in S. aureus is much more threatening 
than the resistance in E. faecalis.  
Depending on the Clinical and Laboratory Standards Institute (former NCCLS) 
the MIC towards vancomycin for glycopeptide susceptible S. aureus (GSSA) is 
" 4 !g/ml, for GISA 4-16 !g/ml, and for GRSA # 32 !g/ml. In addition to GISA 
and GRSA, there are also hetero GISA (hGISA) strains, which are primarily 
susceptible to vancomycin, but contain subpopulations having intermediate MIC 
levels (24).  
The molecular resistance mechanisms, which underlie GISA, are still not well 
understood. However, certain phenotypic characteristics, like cell wall thickening, 
increased PGN synthesis with decreased PGN crosslinking, increased 
incorporation of GlcNAc, altered PBP expression, longer doubling times, 
increased adherence to artificial surfaces, and reduced autolytic activities are 
shared by most of the GISA strains (12, 13, 37, 66). The increased production of 
PGN precursors and the decreased crosslinking leads to an abundance of free 
D-Ala-D-Ala termini, which can be bound by glycopeptide antibiotics. The excess 
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of free binding sites leads to unproductive binding effects, i.e. the glycopeptides 
are all trapped in the outer layers of the cell wall and are thus prevented from 
reaching the cell membrane, where they can directly block the reticulation steps 
of cell wall formation. The fact that during the normal crosslinking process in 
S. aureus, only every 2nd bond is cleaved, leading to a certain number of free D-
Ala-D-Ala binding sites in a highly crosslinked cell wall, indicates that the cell wall 
constitution of S. aureus per se, is promoting resistance (20).  
 
 
 
 
 
 
 
 
Figure 2: Van-resistance regulation to glycopeptide antibiotics  
A) Arrangement of van genes located on Tn1546 responsible for resistance  
B) van gene dependent resistance regulation. Ddl = D-Ala-D-Ala ligase,  
adapted and modified from (21) 
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Typing, evolution, and clonality of MRSA 
The dissemination of MRSA in Europe is characterized by a north-south gradient, 
with being rare in Scandinavian countries and highly prevalent in Southern 
Europe (51). To study the epidemiology and the clonal spread of MRSA, different 
molecular typing techniques are used, among them pulse-field gel 
electrophoresis (PFGE), typing of the variable tandem repeat region of protein A 
(spa typing), multilocus sequence typing (MLST), SCCmec typing or ‘multilocus 
variable number of tandem repeat analysis’ (MLVA). PFGE is based on SmaI 
digestion of bacterial DNA and separation of the DNA fragments according to 
their size by changing the orientation of the electric field periodically (39, 40). 
Spa-typing is based on the sequence typing of a region, which consists out of 24 
bp repeats and is known as the polymorphic X region of protein A and has 
proved its discriminatory use in S. aureus outbreaks and global population 
studies (19, 29). MLST was originally developed to identify hypervirulent lineages 
of Neisseria meningitidis. It was first applied to S. aureus in 2000 and is based on 
the sequence analysis of around 450-bp internal fragments of seven 
housekeeping genes, which are essential in a given species. For each gene 
fragment different sequences are assigned to distinct alleles (e.g. 3-3-1-1-4-4-
16), which can be compared with already known alleles at the MLST website 
(http://www.mlst.net). Thus, the allelic profile of each isolate is characteristic for 
its sequence type (ST). Since there are seven loci with an average of 42 alleles 
present per locus, 427  (more than 200 billion) different allelic profiles and with 
that as much as different strains are possible, making it highly improbable that 
two unrelated genotypes have the same ST (15, 35). Depending on their allelic 
profile, isolates are subdivided in clonal complexes (CC). When at least five of 
seven housekeeping gene alleles are in common with one other member, they 
belong to the same CC and when they have the exact same allelic profile, they 
belong to the same ST, which demonstrates that MLST has an enormous 
discriminatory value (16). SCCmec typing is either based on PCR, amplifying 
parts of the mec gene complex and the ccr genes or based on multiplex PCR 
detecting mecA and either different loci or a single locus on SCCmec (25, 45, 
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68). MLVA is based on the amplification of variable number of tandem repeats 
(VNTR)-containing genes that are found at single genetic loci within the genome. 
This typing method has high discriminatory power within clonal species. VNTRs 
are rapidly evolving short nucleotide sequences (in our assay VNTR length varies 
from 9-500 nucleotides) that are repeated (multiple times) and often vary in their 
copy numbers between strains from various origins. Variation of repeat number 
relies on aberrations during chromosome replication, which is relatively frequent 
in these regions. They have a high mutation rate that leads to the creation of 
length polymorphisms of alleles at the same locus. By designing PCR primers in 
conserved VNTR-flanking regions, these differences are detectable by PCR, 
yielding to different size fragments. The mutation rate of VNTRs is important to 
determine genetic relatedness of a collection of isolates (18, 58). The first MLVA 
methodology was developed in 1997 based on Haemophilus influenzae genome 
sequence and intrinsic repeat variablities (57). The technique was first described 
for typing MRSA in 2003 and was optimized in 2005 in terms of cost- and labor-
saving and discriminatory abilities (18, 50).  
There are two theories regarding the evolution of MRSA strains. One is 
supporting the aspect that all MRSA clones are descendants of one S. aureus, 
which acquired SCCmec on one occasion, and the other theory is supporting the 
aspect that SCCmec was introduced several times into several lineages of 
S. aureus (30, 41). With the above-mentioned molecular typing methods, it was 
possible to reveal the existence of MRSA lineages, which are not related to the 
very first detected MRSA (ST8), thus proving the latter theory. It is also evident 
by the presence of different SCCmec types in isolates with the same ST, that 
MSSA has become MRSA on more than one occasion. Indeed, MLST studies 
revealed that all epidemic hospital MRSA isolates belong to six major lineages or 
clonal complexes (CC8, CC5, CC45, CC30, CC22, CC1) (10). The fact that these 
major MRSA lineages have developed from successful MSSA strains by the 
horizontal transfer of SCCmec and the fact that within the very same successful 
MRSA lineages already some became less responsive to glycopeptides is 
alarming, since glycopeptides are the antibiotics of last resort.   
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Evasion of S. aureus from host response: an overview 
The first line of defense against bacteria invading the host is provided by the 
innate immune system, with polymorphonuclear leukocytes (PMN) being the key 
players. PMN are terminally differentiated cells, descending from pluripotent 
haematopoetic stem cells containing multi-lobed nuclei and a granular cytoplasm. 
PMN have a short half- life of about 12 hours and usually circulate in the blood 
unless they are recruited to sites of infection by chemoattractants to phagocytose 
and kill bacteria. Intracellular killing by PMN occurs due to reactive oxygen 
species (ROS), proteolytic enzymes, and antimicrobial proteins. Extracellular 
killing is caused by degranulation of PMN and the release of antimicrobial 
peptides and enzymes into the extracellular medium (36). Factors of the 
complement system function as chemoattractants and promote the recruitment of 
phagocytic cells to the sites of infection. Furthermore, complement C3b and Fc 
fragments of Ig opsonize bacteria and allow their phagocytosis by PMN and 
macrophages (17). In fact, cells of the monocytic lineage, i.e. monocytes and 
macrophages also play a very important role, since they are the main source of 
pro-inflammatory cytokines during the initial stage of infection. Macrophages and 
Dendritic cells (DCs) are professional antigen presenting cells (APCs), which 
take up bacteria or bacterial components in the tissue. DCs transport them to 
lymphoid organs and present them there to lymphocytes via a MHCII-antigen 
complex. Recognition of the bacterium leading to the induction of an 
inflammation occurs via pattern recognition receptors (PRRs) present on APCs 
and PMN, and pathogen associated molecular patterns (PAMPs) present on 
bacterial cells. B and T lymphocytes are the key players of the adaptive immune 
response. While naïve CD4 T cells, also known as T helper cells, need to be 
primed by DCs before proliferation and subsequent activation of B cells or 
macrophages, naïve B cells don’t need DCs necessarily to be primed for 
proliferation. They either get activated by macrophages presenting antigens or 
take up and process pathogens themselves. In the course of infection with 
extracellular bacteria, the protective immunity is clearly centered on the B cell 
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response, i.e. the secretion of specific antibodies (induced by T helper cells), 
which favor opsonization and phagocytosis of bacteria. In the early phase of an 
infection, when pathogen-specific antibodies are not yet produced, ‘natural 
occurring’ antibodies that can cross-react with many antigens provide the first 
support of humoral defense.  
S. aureus has evolved a multitude of immune evasion mechanisms to escape 
host defense, wherever it is possible. Thus it becomes clear, why S. aureus has 
such a high pathogenicity, once it invades the host.  
This will be demonstrated in the following scenario (Fig. 4):   
Once S. aureus is entering the blood stream, a great proportion is transported by 
the blood flow to lymphoid organs, especially to the spleen, where they come 
across lymphocytes. Some of them encounter monocytes and PMN, which are 
circulating in the blood and which upon contact or upon phagocytosis of bacteria 
secrete pro-inflammatory cytokines like IL-1, IL-6, and TNF$, and chemokines 
like MIP-2 and KC. The secretion of bacteria-derived (e.g. N-formyl peptides) and 
host-derived (chemokines, complement facors) molecules results in the 
recruitment of further host cells. The expression of so-called adhesins, like 
fibrinogen-binding (ClfA/ClfB), fibronectin-binding proteins (FnBPA/FnBPB) and 
collagen binding protein (Cna) on the bacterial surface and the expression of 
extracellular matrix components on endothelial cells enable the adhesion and 
subsequent endocytosis of bacteria (44). These incidents induce the further 
secretion of pro-inflammatory cytokines, chemokines, and the expression of cell 
adhesion molecules like VCAMs and ICAMs and result finally in micro-
environmental changes including vasodilatation. Vasodilatation or active 
disruption of endothelial cell membranes by proteolytic enzymes, enable bacteria 
to penetrate through and enter the parenchyma. There, taken up by 
macrophages, they induce the release of chemoattractants and with that the 
further recruitment of PMN and macrophages into sub-endothelial tissues. After 
two days post infection, the adaptive immune response participates in this 
scenario. DCs present pathogen-derived antigens to naïve T cells and prime 
them for the activation by further APCs. Primed T cells proliferate and in turn 
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activate primed B cells for the secretion of antibodies and macrophages to 
enhance their killing machinery. Priming of B cells usually happens when they 
encounter bacteria in lymphoid organs. There, pathogen-derived peptides are 
presented either by resident APCs, which have taken up and processed bacteria, 
or by APCs, which have taken up bacteria in the periphery and brought them to 
lymphoid organs. 
To evade defensins, secreted by PMN and epithelial cells, S. aureus releases 
certain molecules, which inactivate the functions of these antimicrobial molecules 
by cleaving them either directly e.g. aureolysin, or indirectly, e.g. staphylokinase. 
To escape ROS attack, S. aureus produces catalases, which inactivate toxic 
hydrogen peroxides. Moreover, S. aureus is able to induce apoptosis of host 
cells actively, not only to escape the intracellular attack, but also to disseminate 
thereby throughout the host. Apoptosis of different host cell types can be caused 
by toxin production and/or by the activation of cellular caspases (38, 62, 65). The 
majority of S. aureus strains produces a polysaccharide capsule that functions as 
a cloak of opsonins and reduces the opsonophagocytosis by PMN. Moreover the 
presence of polysaccharide capsules complicates the binding of IgGs that 
enhance the opsonophagocytic uptake of bacteria. Protein A, another important 
molecule contributing to immune evasion is blocks IgG-Fc receptor mediated 
phagocytosis and complement activation by binding to the Fc-part of the 
immunoglobulin. Direct attack of complement and with that direct lysis and 
impaired deposition of immune defense molecules on the surface of S. aureus 
cells, is prevented by the thick cell wall, the polysaccharide capsule and biofilm 
formation. The staphylococcal complement inhibitor (SCIN) is able to block all the 
complement pathways by stabilizing convertase complexes, to prevent their 
degradation and thus their activity (49). Another mechanism to evade host attack 
is to hide intracellular. For a long time, S. aureus was considered to be an 
extracellular pathogen, but meanwhile it could be demonstrated that it is able to 
hide and grow within endothelial cells, forming small colony variants, resulting in 
recurrent infections (59). 
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Fig. 4: Model for innate and adaptive immune response during S. aureus 
sepsis 
In blood S. aureus encounters host phagocytes including monocytes and PMN 
and is taken up. Binding and phagocytosis induces the release of pro-
inflammatory cytokines and chemokines. The blood-flow takes a great proportion 
of entering bacteria directly to lymphoid organs (e.g. spleen), where they 
encounter further phagocytes and lymphocytes. To attach to extracellular matrix 
molecules (ECM) of endothelial cells, bacteria bind host fibronectin by fibronectin 
binding protein A or B (FnBP-A/FnBP-B), or fibrinogen by clumping factor A 
(ClfA) and use it as bridging-molecule to the endothelial layer. Upon attachment, 
they get endocytosed and induce the release of further pro-inflammatory 
cytokines and a general micro-environmental change including vasodilatation. 
Hereby and by secretion of proteolytic enzymes, they penetrate through the 
endothelial layer to sub-endothelial tissue. Taken up by recruited PMNs they may 
be killed or may induce apoptosis and evade. The adaptive immune response 
gets activated, when DCs prime naïve Th cells by Ag-presentation; primed Th 
cells in turn activate primed B cells to secrete antibodies. These pathogen-
specific antibodies opsonize bacteria and enhance thereby phagocytosis by 
macrophages (Mph) and PMN. 
 
 
 
24 
 
 
1. Arthur, M., F. Depardieu, C. Molinas, P. Reynolds, and P. Courvalin. 
1995. The vanZ gene of Tn1546 from Enterococcus faecium BM4147 confers 
resistance to teicoplanin. Gene 154:87-92. 
2. Arthur, M., C. Molinas, T. D. Bugg, G. D. Wright, C. T. Walsh, and P. 
Courvalin. 1992. Evidence for in vivo incorporation of D-lactate into 
peptidoglycan precursors of vancomycin-resistant enterococci. Antimicrob 
Agents Chemother 36:867-9. 
3. Arthur, M., C. Molinas, and P. Courvalin. 1992. The VanS-VanR two-
component regulatory system controls synthesis of depsipeptide peptidoglycan 
precursors in Enterococcus faecium BM4147. J Bacteriol 174:2582-91. 
4. Austin, D. J., K. G. Kristinsson, and R. M. Anderson. 1999. The 
relationship between the volume of antimicrobial consumption in human 
communities and the frequency of resistance. Proc Natl Acad Sci U S A 96:1152-
6. 
5. Baumert, N., C. von Eiff, F. Schaaff, G. Peters, R. A. Proctor, and H. 
G. Sahl. 2002. Physiology and antibiotic susceptibility of Staphylococcus aureus 
small colony variants. Microb Drug Resist 8:253-60. 
6. Beauregard, D. A., D. H. Williams, M. N. Gwynn, and D. J. Knowles. 
1995. Dimerization and membrane anchors in extracellular targeting of 
vancomycin group antibiotics. Antimicrob Agents Chemother 39:781-5. 
7. Berger-Bachi, B., and N. McCallum. 2006. State of the knowledge of 
bacterial resistance. Injury 37 Suppl 2:S20-5. 
8. Bugg, T. D., G. D. Wright, S. Dutka-Malen, M. Arthur, P. Courvalin, 
and C. T. Walsh. 1991. Molecular basis for vancomycin resistance in 
Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan 
precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 
30:10408-15. 
9. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, 
F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and 
 
 
25 
S. K. Fridkin. 2003. Infection with vancomycin-resistant Staphylococcus aureus 
containing the vanA resistance gene. N Engl J Med 348:1342-7. 
10. Cockfield, J. D., S. Pathak, J. D. Edgeworth, and J. A. Lindsay. 2007. 
Rapid determination of hospital-acquired meticillin-resistant Staphylococcus 
aureus lineages. J Med Microbiol 56:614-9. 
11. Couto, I., H. de Lencastre, E. Severina, W. Kloos, J. A. Webster, R. J. 
Hubner, I. S. Sanches, and A. Tomasz. 1996. Ubiquitous presence of a mecA 
homologue in natural isolates of Staphylococcus sciuri. Microb Drug Resist 
2:377-91. 
12. Cui, L., X. Ma, K. Sato, K. Okuma, F. C. Tenover, E. M. Mamizuka, C. 
G. Gemmell, M. N. Kim, M. C. Ploy, N. El-Solh, V. Ferraz, and K. Hiramatsu. 
2003. Cell wall thickening is a common feature of vancomycin resistance in 
Staphylococcus aureus. J Clin Microbiol 41:5-14. 
13. Cui, L., H. Murakami, K. Kuwahara-Arai, H. Hanaki, and K. Hiramatsu. 
2000. Contribution of a thickened cell wall and its glutamine nonamidated 
component to the vancomycin resistance expressed by Staphylococcus aureus 
Mu50. Antimicrob Agents Chemother 44:2276-85. 
14. del Pozo, J. L., and R. Patel. 2007. The challenge of treating biofilm-
associated bacterial infections. Clin Pharmacol Ther 82:204-9. 
15. Enright, M. C., N. P. Day, C. E. Davies, S. J. Peacock, and B. G. Spratt. 
2000. Multilocus sequence typing for characterization of methicillin-resistant and 
methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 
38:1008-15. 
16. Enright, M. C., D. A. Robinson, G. Randle, E. J. Feil, H. Grundmann, 
and B. G. Spratt. 2002. The evolutionary history of methicillin-resistant 
Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A 99:7687-92. 
17. Foster, T. J. 2005. Immune evasion by staphylococci. Nat Rev Microbiol 
3:948-58. 
18. Francois, P., A. Huyghe, Y. Charbonnier, M. Bento, S. Herzig, I. 
Topolski, B. Fleury, D. Lew, P. Vaudaux, S. Harbarth, W. van Leeuwen, A. 
van Belkum, D. S. Blanc, D. Pittet, and J. Schrenzel. 2005. Use of an 
 
 
26 
automated multiple-locus, variable-number tandem repeat-based method for 
rapid and high-throughput genotyping of Staphylococcus aureus isolates. J Clin 
Microbiol 43:3346-55. 
19. Frenay, H. M., A. E. Bunschoten, L. M. Schouls, W. J. van Leeuwen, 
C. M. Vandenbroucke-Grauls, J. Verhoef, and F. R. Mooi. 1996. Molecular 
typing of methicillin-resistant Staphylococcus aureus on the basis of protein A 
gene polymorphism. Eur J Clin Microbiol Infect Dis 15:60-4. 
20. Geisel, R., F. J. Schmitz, A. C. Fluit, and H. Labischinski. 2001. 
Emergence, mechanism, and clinical implications of reduced glycopeptide 
susceptibility in Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 20:685-
97. 
21. Gholizadeh, Y., and P. Courvalin. 2000. Acquired and intrinsic 
glycopeptide resistance in enterococci. Int J Antimicrob Agents 16 Suppl 1:S11-
7. 
22. Goffin, C., and J. M. Ghuysen. 2002. Biochemistry and comparative 
genomics of SxxK superfamily acyltransferases offer a clue to the mycobacterial 
paradox: presence of penicillin-susceptible target proteins versus lack of 
efficiency of penicillin as therapeutic agent. Microbiol Mol Biol Rev 66:702-38, 
table of contents. 
23. Hanssen, A. M., and J. U. Ericson Sollid. 2006. SCCmec in 
staphylococci: genes on the move. FEMS Immunol Med Microbiol 46:8-20. 
24. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, 
Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of 
strains of Staphylococcus aureus heterogeneously resistant to vancomycin. 
Lancet 350:1670-3. 
25. Ito, T., Y. Katayama, K. Asada, N. Mori, K. Tsutsumimoto, C. 
Tiensasitorn, and K. Hiramatsu. 2001. Structural comparison of three types of 
staphylococcal cassette chromosome mec integrated in the chromosome in 
methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 
45:1323-36. 
 
 
27 
26. Katayama, Y., T. Ito, and K. Hiramatsu. 2000. A new class of genetic 
element, staphylococcus cassette chromosome mec, encodes methicillin 
resistance in Staphylococcus aureus. Antimicrob Agents Chemother 44:1549-55. 
27. Kernodle, D. S. 2000. Mechanism of Resistance to beta-Lactam 
Antibiotics. Gram-Positive Pathogens 2000 American Society for 
Microbiology, Washington. 
28. Kluytmans, J., A. van Belkum, and H. Verbrugh. 1997. Nasal carriage 
of Staphylococcus aureus: epidemiology, underlying mechanisms, and 
associated risks. Clin Microbiol Rev 10:505-20. 
29. Koreen, L., S. V. Ramaswamy, E. A. Graviss, S. Naidich, J. M. Musser, 
and B. N. Kreiswirth. 2004. spa typing method for discriminating among 
Staphylococcus aureus isolates: implications for use of a single marker to detect 
genetic micro- and macrovariation. J Clin Microbiol 42:792-9. 
30. Kreiswirth, B., J. Kornblum, R. D. Arbeit, W. Eisner, J. N. Maslow, A. 
McGeer, D. E. Low, and R. P. Novick. 1993. Evidence for a clonal origin of 
methicillin resistance in Staphylococcus aureus. Science 259:227-30. 
31. Leclercq, R., E. Derlot, J. Duval, and P. Courvalin. 1988. Plasmid-
mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N 
Engl J Med 319:157-61. 
32. Lee, C. Y. L. a. J. C. 2000. Staphylococcal capsule. Gram-Positive 
Pathogens American Society for Microbiology, Wahsington. 
33. Lindsay, J. A., and M. T. Holden. 2004. Staphylococcus aureus: 
superbug, super genome? Trends Microbiol 12:378-85. 
34. Lowy, F. D. 1998. Staphylococcus aureus infections. N Engl J Med 
339:520-32. 
35. Maiden, M. C., J. A. Bygraves, E. Feil, G. Morelli, J. E. Russell, R. 
Urwin, Q. Zhang, J. Zhou, K. Zurth, D. A. Caugant, I. M. Feavers, M. 
Achtman, and B. G. Spratt. 1998. Multilocus sequence typing: a portable 
approach to the identification of clones within populations of pathogenic 
microorganisms. Proc Natl Acad Sci U S A 95:3140-5. 
 
 
28 
36. Mayer-Scholl, A., P. Averhoff, and A. Zychlinsky. 2004. How do 
neutrophils and pathogens interact? Curr Opin Microbiol 7:62-6. 
37. McCallum, N., H. Karauzum, R. Getzmann, M. Bischoff, P. 
Majcherczyk, B. Berger-Bachi, and R. Landmann. 2006. In vivo survival of 
teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin 
resistance. Antimicrob Agents Chemother 50:2352-60. 
38. Menzies, B. E., and I. Kourteva. 2000. Staphylococcus aureus alpha-
toxin induces apoptosis in endothelial cells. FEMS Immunol Med Microbiol 29:39-
45. 
39. Mulvey, M. R., L. Chui, J. Ismail, L. Louie, C. Murphy, N. Chang, and 
M. Alfa. 2001. Development of a Canadian standardized protocol for subtyping 
methicillin-resistant Staphylococcus aureus using pulsed-field gel 
electrophoresis. J Clin Microbiol 39:3481-5. 
40. Murchan, S., M. E. Kaufmann, A. Deplano, R. de Ryck, M. Struelens, 
C. E. Zinn, V. Fussing, S. Salmenlinna, J. Vuopio-Varkila, N. El Solh, C. 
Cuny, W. Witte, P. T. Tassios, N. Legakis, W. van Leeuwen, A. van Belkum, 
A. Vindel, I. Laconcha, J. Garaizar, S. Haeggman, B. Olsson-Liljequist, U. 
Ransjo, G. Coombes, and B. Cookson. 2003. Harmonization of pulsed-field gel 
electrophoresis protocols for epidemiological typing of strains of methicillin-
resistant Staphylococcus aureus: a single approach developed by consensus in 
10 European laboratories and its application for tracing the spread of related 
strains. J Clin Microbiol 41:1574-85. 
41. Musser, J. M., and V. Kapur. 1992. Clonal analysis of methicillin-resistant 
Staphylococcus aureus strains from intercontinental sources: association of the 
mec gene with divergent phylogenetic lineages implies dissemination by 
horizontal transfer and recombination. J Clin Microbiol 30:2058-63. 
42. Nagaev, I., J. Bjorkman, D. I. Andersson, and D. Hughes. 2001. 
Biological cost and compensatory evolution in fusidic acid-resistant 
Staphylococcus aureus. Mol Microbiol 40:433-9. 
 
 
29 
43. Noble, W. C., Z. Virani, and R. G. Cree. 1992. Co-transfer of vancomycin 
and other resistance genes from Enterococcus faecalis NCTC 12201 to 
Staphylococcus aureus. FEMS Microbiol Lett 72:195-8. 
44. Ogawa, S. K., E. R. Yurberg, V. B. Hatcher, M. A. Levitt, and F. D. 
Lowy. 1985. Bacterial adherence to human endothelial cells in vitro. Infect 
Immun 50:218-24. 
45. Oliveira, D. C., and H. de Lencastre. 2002. Multiplex PCR strategy for 
rapid identification of structural types and variants of the mec element in 
methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 
46:2155-61. 
46. Pinho, M. G., H. de Lencastre, and A. Tomasz. 2001. An acquired and a 
native penicillin-binding protein cooperate in building the cell wall of drug-
resistant staphylococci. Proc Natl Acad Sci U S A 98:10886-91. 
47. Reynolds, P. E. 1989. Structure, biochemistry and mechanism of action 
of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 8:943-50. 
48. Reynolds, P. E., F. Depardieu, S. Dutka-Malen, M. Arthur, and P. 
Courvalin. 1994. Glycopeptide resistance mediated by enterococcal transposon 
Tn1546 requires production of VanX for hydrolysis of D-alanyl-D-alanine. Mol 
Microbiol 13:1065-70. 
49. Rooijakkers, S. H., M. Ruyken, A. Roos, M. R. Daha, J. S. Presanis, R. 
B. Sim, W. J. van Wamel, K. P. van Kessel, and J. A. van Strijp. 2005. 
Immune evasion by a staphylococcal complement inhibitor that acts on C3 
convertases. Nat Immunol 6:920-7. 
50. Sabat, A., J. Krzyszton-Russjan, W. Strzalka, R. Filipek, K. Kosowska, 
W. Hryniewicz, J. Travis, and J. Potempa. 2003. New method for typing 
Staphylococcus aureus strains: multiple-locus variable-number tandem repeat 
analysis of polymorphism and genetic relationships of clinical isolates. J Clin 
Microbiol 41:1801-4. 
51. Spencer, R. C. 1996. Predominant pathogens found in the European 
Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis 
15:281-5. 
 
 
30 
52. Spika, J. S., P. K. Peterson, B. J. Wilkinson, D. E. Hammerschmidt, H. 
A. Verbrugh, J. Verhoef, and P. G. Quie. 1982. Role of peptidoglycan from 
Staphylococcus aureus in leukopenia, thrombocytopenia, and complement 
activation associated with bacteremia. J Infect Dis 146:227-34. 
53. Stewart, P. S., and J. W. Costerton. 2001. Antibiotic resistance of 
bacteria in biofilms. Lancet 358:135-8. 
54. Swartz, M. N. 1997. Use of antimicrobial agents and drug resistance. N 
Engl J Med 337:491-2. 
55. Tenover, R. P. G. a. F. 2000. The Epidemiology of Staphylococcus 
Infections  Gram-Positive Pathogens American Society for Microbiology. 
56. Timmerman, C. P., E. Mattsson, L. Martinez-Martinez, L. De Graaf, J. 
A. Van Strijp, H. A. Verbrugh, J. Verhoef, and A. Fleer. 1993. Induction of 
release of tumor necrosis factor from human monocytes by staphylococci and 
staphylococcal peptidoglycans. Infect Immun 61:4167-72. 
57. van Belkum, A., S. Scherer, W. van Leeuwen, D. Willemse, L. van 
Alphen, and H. Verbrugh. 1997. Variable number of tandem repeats in clinical 
strains of Haemophilus influenzae. Infect Immun 65:5017-27. 
58. vanBelkum, A. 2006. Tracing isolates of bacterial species by multilocus 
variable number of tandem repeat analysis (MLVA). FEMS Immunol Med 
Microbiol 49:22-27. 
59. Vesga, O., M. C. Groeschel, M. F. Otten, D. W. Brar, J. M. Vann, and R. 
A. Proctor. 1996. Staphylococcus aureus small colony variants are induced by 
the endothelial cell intracellular milieu. J Infect Dis 173:739-42. 
60. von Eiff, C., K. Becker, K. Machka, H. Stammer, and G. Peters. 2001. 
Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. 
N Engl J Med 344:11-6. 
61. Walsh, F. M., and S. G. Amyes. 2004. Microbiology and drug resistance 
mechanisms of fully resistant pathogens. Curr Opin Microbiol 7:439-44. 
62. Weglarczyk, K., J. Baran, M. Zembala, and J. Pryjma. 2004. Caspase-8 
activation precedes alterations of mitochondrial membrane potential during 
 
 
31 
monocyte apoptosis induced by phagocytosis and killing of Staphylococcus 
aureus. Infect Immun 72:2590-7. 
63. Wertheim, H. F., D. C. Melles, M. C. Vos, W. van Leeuwen, A. van 
Belkum, H. A. Verbrugh, and J. L. Nouwen. 2005. The role of nasal carriage in 
Staphylococcus aureus infections. Lancet Infect Dis 5:751-62. 
64. Wertheim, H. F., M. C. Vos, A. Ott, A. van Belkum, A. Voss, J. A. 
Kluytmans, P. H. van Keulen, C. M. Vandenbroucke-Grauls, M. H. Meester, 
and H. A. Verbrugh. 2004. Risk and outcome of nosocomial Staphylococcus 
aureus bacteraemia in nasal carriers versus non-carriers. Lancet 364:703-5. 
65. Wesson, C. A., J. Deringer, L. E. Liou, K. W. Bayles, G. A. Bohach, 
and W. R. Trumble. 2000. Apoptosis induced by Staphylococcus aureus in 
epithelial cells utilizes a mechanism involving caspases 8 and 3. Infect Immun 
68:2998-3001. 
66. Williams, I., W. A. Venables, D. Lloyd, F. Paul, and I. Critchley. 1997. 
The effects of adherence to silicone surfaces on antibiotic susceptibility in 
Staphylococcus aureus. Microbiology 143 ( Pt 7):2407-13. 
67. Wright, G. D., C. Molinas, M. Arthur, P. Courvalin, and C. T. Walsh. 
1992. Characterization of vanY, a DD-carboxypeptidase from vancomycin-
resistant Enterococcus faecium BM4147. Antimicrob Agents Chemother 
36:1514-8. 
68. Zhang, K., J. A. McClure, S. Elsayed, T. Louie, and J. M. Conly. 2005. 
Novel multiplex PCR assay for characterization and concomitant subtyping of 
staphylococcal cassette chromosome mec types I to V in methicillin-resistant 
Staphylococcus aureus. J Clin Microbiol 43:5026-33. 
 
 
 
 
32 
 
 
Chapter I 
 
 
IN VIVO SURVIVAL OF TEICOPLAIN-RESISTANT 
STAPHYLOCOCCUS AUREUS AND FITNESS COST OF 
TEICOPLANIN RESISTANCE 
 
Nadine McCallum1*#, Hatice Karauzum2*, Roger Getzmann2, Markus Bischoff1, 
Paul Majcherczyk3, Brigitte  Berger-Bächi1, Regine Landmann2 
 
 
 
1Department of Medical Microbiology, University of Zürich, Gloriastr. 32,  
8006 Zürich, Switzerland.  
 
2Division of Infectious Diseases, Department of Research, University Hospital, 
Basel, Switzerland. 
 
3Department of Fundamental Microbiology, Bâtiment Biophore, Quartier UNIL-
Sorge, University of Lausanne, 1015 Lausanne, Switzerland. 
 
 
 
*These two authors contributed equally to this study. 
 
 
Published in Antimicrobial Agents and Chemotherapy, July 2006, 50:2352-2360 
 
 
33 
ABSTRACT 
Glycopeptide resistance, in a set of in vitro step-selected teicoplanin resistant 
mutants derived from susceptible Staphylococcus aureus SA113, was associated 
with slower growth, thickening of the bacterial cell wall, increased N-
acetylglucosamine incorporation, and decreased hemolysis. Differential 
transcriptome analysis showed that as resistance increased, some virulence-
associated genes became downregulated. In a mouse tissue cage infection 
model, an inoculum of 104 colony forming units (CFU) of strain SA113 rapidly 
produced a high bacterial load infection, which triggered MIP-2 release, 
leukocyte infiltration and reduced leukocyte viability. In contrast, with the same 
inoculum of the isogenic glycopeptide-resistant derivative NM67, CFUs initally 
decreased, resulting in the elimination of the mutant in three out of seven cages. 
In the four cages in which NM67 survived, it partially regained wild-type 
characteristics, including thinning of the cell wall, reduced N-acetylglucosamine 
uptake and increased hemolysis, however, the survivors also became teicoplanin 
hypersusceptible. The elimination of the teicoplanin-resistant mutants and 
selection of teicoplanin hypersusceptible survivors in the tissue cages indicated 
that glycopeptide resistance imposes a fitness burden on S. aureus and is 
selected against in vivo; with restoration of fitness incurring the price of 
resistance loss. 
 
 
34 
INTRODUCTION 
Over 15 years ago, the first clinical methicillin resistant Staphylococcus aureus 
(MRSA) isolates with decreased susceptibility to the glycopeptide antibiotic 
teicoplanin were described (27). In the interceding years, glycopeptide 
intermediate resistant S. aureus (GISA) isolates have been recovered from most 
parts of the world (reviewed in 24, 58). GISA is the general term used to describe 
strains with intermediate glycopeptide MICs ranging from 4-16 µg/ml that are 
usually isolated from patients after prolonged glycopeptide exposure (54). 
Resistance arises intrinsically upon glycopeptide exposure, as the result of 
multiple mutations and/or alterations in gene expression (47, 49, 51). Several of 
the clinical and laboratory GISA described share phenotypic similarities; most 
commonly a modification of the cell wall, reducing the amount of glycopeptide 
able to reach its target at the cell membrane (13, 14, 23, 24, 50). Common GISA 
features include cell wall thickening, decreased peptidoglycan crosslinking, 
decreased growth rate and hemolysis, alterations in rates of autolysis and 
changes in the structure and/or abundance of cell wall teichoic acids (7-9, 13, 41, 
42, 49, 50). However, there is still little known about the genetic basis of this 
phenotype and there is no universal genetic marker typical for all GISA isolates.  
Certain genetic observations have been frequently documented in both clinical 
and laboratory derived GISA, such as increased PBP2 and decreased PBP4 
expression (10, 23, 38, 43, 48), which are associated with cell wall modifications 
leading to increased cell wall synthesis and decreased peptidoglycan 
crosslinking. However, this observation is not true for all GISA strains and these 
changes in penicillin binding protein abundance are not sufficient in themselves 
to create a GISA phenotype (23). Several genetic alterations have been shown to 
only contribute to increased resistance in a single or restricted number of strains, 
including: overexpression of the global regulator SigB (2, 51) and the two 
component sensor transducer VraSR (32); defective agr function (36, 46); 
alterations in the expression of genes encoding autolysins or effecting autolytic 
function (7, 8, 28, 41, 49) and genes involved in carbohydrate metabolism and 
cell wall synthesis (29); inactivation of tcaA, a membrane protein of unknown 
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function (34); and inactivation of mprF (fmtC), a membrane protein involved in 
the biosynthesis of the positively charged cell membrane lipid 
lysylphosphatidylglycerol, was found to increase resistance levels in glycopeptide 
susceptible strains, but to decrease resistance in GISA (39, 45).  
The limited number of global transcriptome analyses performed, have indicated 
that multiple mutational and regulatory events are causing numerous metabolic 
changes in GISA (12, 33, 37). The full genetic basis of GISA formation has not 
been elucidated in any strain, but it appears that there are likely to be several 
different, as yet undiscovered, loci and pathways involved in resistance 
formation.  
Increased production of peptidoglycan, required to facilitate the construction of a 
thicker cell wall, is an energetically unfavorable phenotype, as evidenced by the 
slower growth rate of GISA strains, and is probably the main reason that GISA 
strains are not isolated more frequently (13, 35, 49). This also contributes to the 
reported instability of the resistance phenotype in the absence of selection 
pressure (6, 13). Reversion from a GISA to a GSSA phenotype could be driven 
by a combination of the reversal of regulatory events and forward mutations, 
which lead to reclaimed fitness at the cost of decreased resistance. It is 
speculated that in the absence of drug pressure, mutants with greater fitness 
emerge spontaneously and dominate the population (13).  
The fitness of S. aureus cells inside a host is governed by intrinsic properties 
such as the rate at which they reproduce and the rate at which they are cleared 
by host defense mechanisms. Since the fitness of glycopeptide resistant strains 
in infected hosts is unknown, we chose to investigate the in vivo behavior of a 
teicoplanin resistant strain in a defined murine infection model. The tissue cage 
model was first described and extensively characterized in the guinea pig (62) 
and then adapted to the mouse (31). Low inocula, 103 colony forming units 
(CFU), of S. aureus cause a persistent local infection, which never becomes 
systemic. The absence of vascularization limits serum factors and the presence 
of leukocytes, which are attracted by the polymer implant before infection and 
show weak functional capacity (61), contribute to pathogenesis in this model. 
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Persistence is facilitated by progressive leukocyte apoptosis and necrosis (30). 
This model accurately mimics orthopedic implant infections. Because bacteria 
are inoculated directly into the cage, with no adherence and invasion step 
through epithelia, the minimal infective dose of staphylococci which is required 
for a persistent infection reflects virulence. Accordingly, virulence is dependent 
on the resistance of S. aureus to extracellular phagocyte-dependent killing in the 
immunocompetent host. Therefore this model differentiates S. aureus strains that 
have altered susceptibilities to bactericidal mechanisms. The host response is 
mediated exclusively by phagocytes and comprises defensins, reactive oxygen 
species, cytokines, chemokines, leukocyte infiltration and apoptosis. 
S. aureus SA113 was passaged several times on teicoplanin to obtain an 
isogenic mutant with intrinsically acquired glycopeptide resistance. The stability 
of the resistance phenotype and accompanying cell wall characteristics were 
monitored in vitro, prior to and during infection in a mouse tissue-cage infection 
model, to assess the impact of the GISA phenotype on in vivo survival. A 
transcriptome comparison of the mutant and wildtype was performed, and the 
transcription of selected differentially regulated genes was profiled in vitro and 
from tissue cage isolates.  
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MATERIALS AND METHODS 
Bacterial strains and culture conditions. Strains were routinely cultured at 
37°C on sheep blood agar or in brain heart infusion (BHI) broth (BBLTM Becton 
Dickinson, MD. USA) and stored as frozen stocks in skim milk at -80°C. A series 
of isogenic strains with increasing glycopeptide resistance levels was generated 
from susceptible S. aureus strain SA113 (26), by plating dilutions of an overnight 
culture on BHI agar containing increasing concentrations of teicoplanin. Ten 
single colonies growing at the highest concentration were selected and 
subcultured twice on nonselective agar to ensure the stability of the phenotype. 
Their resistance levels were compared to the susceptible parent on teicoplanin 
gradient plates. The strain with the highest increase in teicoplanin resistance, 1st 
step mutant NM18, was then used to repeat the selection and to obtain the most 
resistant 2nd step mutant NM30; which was used to obtain a 3rd step mutant 
NM67. To ensure clonality was maintained, all strains were tested by pulsed field 
gel electrophoresis of SmaI-digested chromosomal DNA according to the 
protocol of Wada (57). Growth rate experiments were performed as previously 
described (18).  
For measurement of N-acetylglucosamine uptake and release, HPLC, autolysis 
and transmission electron microscopy on cells recovered from tissue cages, 50 µl 
of tissue cage fluid (TCF) were centrifuged at 4000 rpm for five minutes. The 
pellet was resuspended in BHI medium and grown overnight at 37°C. The 
overnight culture was pelleted and transferred into cryovials containing beads in 
cryopreservative for storage (Pro Lab Microbank Bacterial Preservation System 
Green, Basel, CH). After inverting vials 4-5 times, cryopreservative was aspirated 
and the beads were stored at -70°C. 
 
Stability of resistant mutants in vitro. The stability of the teicoplanin resistance 
phenotype was monitored under in vitro culture conditions. Twenty ml BHI 
cultures of SA113 and NM67 were either subjected to prolonged stationary 
culture conditions at 37°C for 8 days, or subcultured daily in 20 ml of fresh broth, 
using a dilution factor of 104, over the 8 day period.  
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Resistance tests. Minimal inhibitory concentrations (MIC) of glycopeptides were 
determined by E-test (AB-Biodisk, Solna, Sweden) on brain heart infusion (BHI, 
BBLTM) plates with an inoculum of 2 McFarland standard and incubation at 37°C 
for 48 h. Lysostaphin MICs were determined by broth microdilution in BHI as 
recommended by the CLSI/NCCLS (25). For population analysis profiles, 
dilutions of an overnight culture were spread on BHI agar plates containing 
increasing concentrations of teicoplanin. For population analyses of strains ex 
vivo, 50 !l of TCF was grown overnight and then adjusted to McFarland 0.5 
before plating. The CFU were determined after 48 h incubation at 37°C. 
 
Hemolysis assays. Hemolytic activities were compared on sheep blood agar 
plates. Wells were stamped out of the agar and filled with 100 µl of filtered 
supernatant, from cultures grown in BHI for 24 h. Plates were incubated 
overnight at 37°C. 
 
Tissue cage model. Male C57BL/6 mice (12–16 weeks old) were anesthetized 
and sterile cylindrical teflon tissue cages were implanted subcutaneously in their 
backs, as described previously (31). Two weeks after surgery, sterility of tissue 
cages was verified, and 200 !l of a suspension from stationary overnight cultures 
containing 104 CFU, were injected percutaneously. Mice never developed 
bacteremia and showed no weight change during 8 days of infection. 
Mice were anesthesized after days 1, 2, 5 and 8 of infection, and TCF samples of 
150 !l were collected by percutaneous aspiration and transferred into tubes 
containing 15 !l of 1.5% EDTA. The load of planktonic bacteria in TCF was 
determined by serial dilutions of the samples on BHI agar plates. Leukocytes 
from TCF were quantified with a Coulter counter. The percentage of viable 
leukocytes was assessed by trypan blue exclusion. MIP-2 was determined by 
sandwich ELISA (R&D Systems, Minneapolis). Mice were kept under specific 
pathogenfree conditions in the Animal House of the Department of Research, 
University Hospital Basel, and animal experimentation guidelines were followed 
according to the regulations of Swiss veterinary law. 
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Statistics. Median and lowest quartiles were calculated from each group of 
strains on all days of investigation. ANOVA for repeated measures, with Scheffé 
posthoc tests, was used to compare SA113 and NM67 during infection. 
 
Sampling, RNA isolation, and transcriptional profiling. Differential microarray 
analysis of the transcriptomes of SA113 and NM67 was carried out on 
exponentially growing cultures in Luria-Bertani (LB), harvested at an OD600 of 2, 
as previously described (3).  
 
RNA extraction and Northern hybridisation. RNA isolation from bacteria 
grown in shaking LB cultures and Northern blots were performed as described 
earlier (34). Ten micrograms of total RNA from each sample were separated 
through a 1.5% agarose-20 mM guanidine thiocyanate gel in 1 x TBE running 
buffer (21). ORFs selected for probe amplification and the primers used, are 
shown in Table 1. All Northerns were performed at least twice on independently 
isolated RNA samples.  
 
Incorporation and release of N-acetylglucosamine. The incorporation of 14C-
labelled N-acetylglucosamine (Amersham, USA) into cells in resting medium and 
the release of 14C-labelled N-acetylglucosamine into the culture medium were 
measured essentially as described by Hanaki (23), except that the cells were 
pregrown in BHI.  
 
Cell wall composition. Cell walls were purified from bacteria grown to 
exponential or stationary phase in BHI broth. Teichoic acids were removed from 
the cell walls by gently mixing the cell wall suspension in hydrofluoric acid (49%) 
for 48 h at 4°C. The peptidoglycan was recovered, digested with muramidase 
(Sigma), reduced, and the muropeptides were separated by HPLC as described 
by de Jonge et al. (17). Eluted material was detected by its absorbance at 210 
nm and principal peaks identified using muropeptide peak libraries from 
S. aureus COL (5). The degree of muropeptide cross-linking was calculated by 
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quantification of the relative amounts of monomers, dimers, trimers, and 
oligomers in the muropeptide digest according to Snowden et al. (52). 
 
Spontaneous autolysis. Cells grown to an OD600 of 0.7 in BHI were pelleted, 
washed once with saline and resuspended in 0.01 M sodium phosphate buffer 
pH 7.0, to an OD600 of 0.8. The cell suspension was incubated at 37°C with 
continuous gentle shaking. Decrease in OD600 was monitored every hour for 5 h.  
 
Zymography. Exponentially growing cells, cultured in BHI, were harvested at an 
OD600 of 1.0. Autolysins were extracted and analysed according to the method 
described by Hanaki et al. (23), using cell-wall extracts of S. aureus SA113 as 
the substrate. Band intensities were scanned and quantified. 
Transmission electron microscopy. Cells grown overnight were processed for 
thin-sectioning electron microscopy as described by Pante et al. (40). Electron 
micrographs were recorded with a Zeiss LEO 910 transmission electron 
microscope.  
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Table 1.  Primers used in this study 
Gene/orfa Primer Sequence (5’-3’) 
   
spa (SA0107) spa F TGTAGGTATTGCATCTGTAA 
 spa R AAGTTAGGCATATTCAAGAT 
   
SA0112 SA0112 F GTTAGAGTATATGAATACCT 
 SA0112 R TACTCATACCCATAATGCTA 
   
SA0184 SA0184 F CAAGTGACTTACCTCATAGA 
 SA0184 R AACACTTCAGATACACCAGT 
   
geh (SA0309) geh F TCATGCTGAACGTAATGGAT 
 geh R CACTTACACTTGCTTGATGT 
   
SA1007 SA1007 F TAATGAATCCTGTCGCTAAT 
 SA1007 R TTCAGTGTATGACCAATCGA 
   
nuc (SA1160) nuc F GTAGGTGTATTAGCATTTCA 
 nuc R GTACATACGATCTTTACTTA 
   
SA1898 SA1898 F ATGGCGCAATCAAATGATCA 
 SA1898 R GATGAGCATTCACATTTAGA 
   
SA2097 SA2097 F TAGTAGGTCAAGCACATCAT 
 SA2097 R CCTTCAGAAGATTGTAGGAT 
   
sbi (SA2206) sbi F AGAACGTGCACAAGAAGTAT 
 sbi R CTACTAATGCGTCTAATTGT 
   
opp-1A (SA2255) opp-1A F CTTGTACGTAACACGAAAGA 
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 opp-1A R TTAACTTGATAGTCACCTCT 
   
gbsA (SA2406) gbsA F CGTTAGAAGAATCATATGCA 
 gbsA R AAGTTCCAAGGCAATATTCG 
   
icaA (SA2459) icaA F TGGATGAATTAGAAGGCATT 
 icaA R CGGTTCATACTTAATACGAT 
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RESULTS 
Phenotype and in vitro stability of the teicoplanin resistant mutants. A 
series of three mutants, NM18, NM30 and NM67, with sequentially increasing 
teicoplanin MICs of 16, 48 and 64 !g/ml, respectively, were generated from the 
susceptible parent strain SA113 (teicoplanin MIC 3 !g/ml). They showed 
heterogeneous resistance profiles on teicoplanin, segregating subpopulations 
resistant to higher concentrations of the drug (Fig. 1). Parallel to the increasing 
teicoplanin resistance, the vancomycin MIC rose from 4 !g/ml in SA113 to 
24 !g/ml in NM67; the minimum doubling time increased from 25.7 + 1.7 min in 
SA113 to 37.6 + 1.4 min in NM67; and hemolysin production, which was clearly 
visible in SA113, was undetectable in NM67 (refer to Fig. 6B). Initial studies 
demonstrated that NM67 incorporated, within 120 min, approximately 2.7 times 
(n = 3, p < 0.05) more 14C-labelled N-acetylglucosamine than SA113, a feature of 
many clinical GISA isolates which is associated with increased cell wall thickness 
(20, 23). There were no significant differences between SA113 and NM67 in their 
release rates of 14C-labelled N-acetylglucosamine into the culture supernatant 
(data not shown). The cells of the teicoplanin-resistant strain NM67 were 
significantly smaller, but their cell wall was significantly thicker (cytoplasm 
diameter 797.4 + 21.7 nm; cell wall thickness 54.9 + 2.3 nm), compared with 
parent SA113 (961.1 + 38.3 nm, p < 0.001; 47.3 + 2.2 nm, p < 0.05). 
Muropeptide analysis showed that the degree of peptidoglycan crosslinking in 
SA113 (71.3 %) and NM67 (70.9 %) did not differ significantly. 
Glycopeptide resistance phenotypes were stable upon storage of the strains at  
-80°C and through several subcultures on drug free sheep blood agar plates. 
However, upon prolonged incubation or repeated daily subculture, over 8 days in 
liquid culture, decreases in teicoplanin resistance occurred. Loss of resistance 
was very stochastic with repeated experiments giving widely varying results. 
After 8 days, resistance had always decreased, with MICs ranging from 6 to 
24 mg/ml (data not shown). 
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Figure 1. Resistance profiles of teicoplanin-selected mutants. Population 
analysis profile of: filled circle, susceptible strain SA113; filled diamond, 1st step 
mutant NM18; filled square, 2nd step mutant NM3; and filled triangle, 3rd step 
mutant NM67. 
 
 
 
Downregulation of virulence-associated genes in NM67. Transcriptional 
differences were evaluated between the teicoplanin resistant mutant NM67 and 
its susceptible parent SA113, in the mid exponential growth phase. In the mutant, 
there were no genes upregulated by three-fold or more over the parent, despite 
the relevant increase in cell wall thickness and N-acetylglucosamine uptake. In 
contrast, 26 ORFs were downregulated more than three-fold in NM67 (Table 2). 
Downregulated ORFs comprised 12 loci, consisting of seven single gene loci and 
five multi-gene clusters, most of which are likely to play a role in virulence. These 
included, lipase (geh), alpha-hemolysin precursor (SA1007), nuclease (nuc), and 
the secretory antigen (SA2097), which is similar to the secretory antigen 
precursor ssaA (1); protein A (spa) and IgG-binding surface sprotein (sbi) which 
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are involved in the evasion of host defenses (60); betA and gbsA playing a role in 
osmoprotection (4); the icaA operon which is linked to biofilm formation and 
increased virulence in mouse tissue cage infections (19); and the large operon 
SA0112-SA120 which is involved in siderophore biosynthesis (15). 
Northern blots of RNA harvested in early exponential- and mid-exponential 
growth phase substantiated the microarray results and in some cases showed at 
which step during the three step-selection process transcription had decreased. 
Transcription of spa and opp-1A was already downregulated after the 1st 
selection step in NM18, the transcript abundance of sbi was slightly lower in the 
1st step mutant but decreased more significantly after the 2nd selection step in 
NM30, while transcription of SA1007 and geh was only downregulated after the 
2nd selection step (Fig. 2A). The transcription levels of these five genes 
correlated with the microarray results, confirming the overall validity of the 
microarrays. Four of the probes, SA0112, icaA, gbsA and SA0184 produced 
unreadable Northerns (data not shown), most likely due the large size of 
polycistronic transcripts, but possibly also due to poor transfer, degradation, or 
low expression levels. The remaining genes either showed no alteration in 
transcription, such as SA2097, or gave results that did not agree with the 
microarray, with the transcript abundance of SA1898 and nuc appearing to have 
slightly increased in the teicoplanin resistant mutants (data not shown). This 
discrepancy could indicate periodic fluctuations in gene expression that were not 
captured in the intervals measured, or could simply reflect subtle differences 
between the growth conditions or extraction methods used to prepare the RNA 
for the microarrays and the Northern blots. 
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Table 2. Genes downregulated in the step selected teicoplanin resistant mutant 
ORF 
numbera 
N315 
gene 
Description/putative functionb Fold 
downregulation  
SA0107 spa Protein A 4.5 
    
SA0112  Siderophore biosynthesis 8.2 
SA0113  Siderophore biosynthesis 7.6 
SA0114  Siderophore biosynthesis 6.1 
SA0115  Siderophore biosynthesis 4.4 
SA0116  Siderophore biosynthesis 7.7 
SA0117  Siderophore biosynthesis 5.7 
SA0118  Siderophore biosynthesis 6.4 
SA0119  Siderophore biosynthesis 5.7 
SA0120  Siderophore biosynthesis 4.6 
    
SA0184  Conserved hypothetical protein of 
unknown function 
4.0 
SA0185  Glucokinase regulator-related protein 
(carbohydrate transport and 
metabolism) 
3.7 
SA0186  Homologue of PTS system IIBC 
components (carbohydrate transport 
and metabolism) 
4.2 
    
SA0309 geh Glycerol ester hydrolase - lipase 3.8 
    
SA1007  Alpha hemolysin precursor 5.1 
    
SA1160 nuc Thermostable staphylococcal nuclease 6.2 
    
SA1898  Hypothetical, similar to SceD precursor 7.6 
    
SA2097  Secretory antigen precursor SsaA 
homologue 
4.3 
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SA2206 sbi  IgG-binding protein SBI 6.3 
    
SA2255 opp-1A  Oligopeptide tansporter substrate 
binding domain 
4.4 
SA2252 opp-1D Oligopeptide transporter ATpase 
domain 
3.8 
    
SA2405 betA Choline dehydrogenase 
(osmoprotection) 
3.7 
SA2406 gbsA  Glycine betaine aldehyde 
dehydrogenase (osmoprotection) 
3.7 
    
SA2459 icaA  Intercellular adhesion protein A (biofilm 
production) 
5.2 
SA2460 icaD Intercellular adhesion protein D 
(biofilm production) 
5.4 
SA2461 icaB Intercellular adhesion protein B (biofilm 
production) 
5.3 
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Figure 2. Changes in gene expression upon acquisition and loss of 
glycopeptide resistance. A) Transcription of differentially expressed genes in 
SA113 and the three step-selected teicoplanin-resistant mutants NM18, NM30 
and NM67, at early- (OD600 = 0.5) and mid-exponential phase (OD600 = 2). B) 
Transcription profiles of the same genes from SA113, and NM67 cells recovered 
from mouse TCF on days 1 and 8 of infection. 
 
 
 
Survival in the mouse cage infection model. To assess tissue cage survival, 
equal numbers of SA113 and NM67 cells were inoculated into mouse tissue 
cages, and infection was monitored over 8 days. The bacterial load of SA113 
steadily increased over the 8 days in the TCF. However, three out of seven mice 
infected with an identical dose of NM67 completely cleared the bacteria within 5 
days. In the remaining four mice, NM67 decreased in numbers after the first day 
post infection, as in mice clearing the bacteria, (p < 0.01 day 1, p < 0.05 day 2, 
Fig. 3A) and then resumed growth. The recovering bacteria reached the same 
final cell density as the wildtype after 8 days (Fig. 3A). This suggested that NM67 
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was less fit than the wildtype parent, and that it was actively cleared in the tissue 
cages, giving rise to the outgrowth of a surviving population.  
 
Host response. During infection, inflammation in the TCF is marked by 
granulocyte influx, apoptosis and chemokine release (30, 31). Baseline leukocyte 
counts of 1x104 ± 3.1x103 cells/!l, consisting of a larger polymorphonuclear 
neutrophil (PMN) (91 % ± 3 %) and a smaller monocyte (9 % ± 3 %) fraction 
were found in uninfected tissue cages, in agreement with previous reports (16, 
62). The macrophage inflammatory protein (MIP-2, CXCL2) is a murine 
neutrophil chemotactic factor with a function similar to IL-8 in humans (55). After 
infection with SA113, the MIP-2 concentration in TCF steadily increased from day 
1 through day 8. NM67 survivors induced two-fold less MIP-2 than SA113 after 
the eight days. (p < 0.05, Fig. 3B).  
MIP-2 is the major leukocyte attractant; accordingly leukocyte infiltration into 
tissue cages inoculated with SA113 or NM67 showed a time-dependent increase 
during infection, and correlated with the bacterial load of the TCF (Fig. 3C). Eight 
days after infection the concentration of leukocytes was two-fold higher in cages 
containing SA113 than in those with the surviving NM67 (p < 0.05). Mice which 
were mock-infected, or which were able to clear the infection, showed no 
increased leukocyte infiltration (Fig. 3C). Since the MIP-2 levels and consequent 
leukocyte infiltration were proportional to the bacterial load in both strains, it 
seemed likely that the surviving NM67 cells may have had a similar capacity to 
induce MIP-2 and a similar chemoattractant potential to SA113.  
The leukocyte viability within the TCF during infection was evaluated, because 
staphylococci are known to kill eukaryotic cells (22). In cages infected with 
SA113 a  significant decline of the proportion of viable leukocytes (from 100% to 
36%) was observed on day 8 post infection (p < 0.05). Leukocytes in mice which 
cleared NM67 did not lose viability. In mice successfully infected with NM67, 
however, the decrease in leukocyte viability started only two days post infection 
(Fig. 3D), coinciding in time with the emergence of the surviving NM67 
subpopulation. 
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Figure 3. Bacterial load and host response after infection of tissue cages 
with strains SA113 and NM67. In vivo bacterial growth and host response over 
8 days in tissue cages infected with 104 CFU of S. aureus. SA113 (n = 5, solid 
circle); NM67 growing in tissue cages (n = 4, solid triangle); NM67 cleared from 
tissue cages during infection (n = 3, empty triangle); and values in uninfected 
cages (empty square). Time 0, values before infection. A) bacterial load in TCF, 
** p < 0.01, day 1 and * p < 0.05 day 2; B) macrophage inflammatory protein 
MIP-2 concentrations in TCF, * p < 0.05  day 8; C) leukocyte numbers in TCF, 
* p < 0.05 day 8; D) viable leukocytes in TCF, * p < 0.05 day 8. Median values 
are plotted for each group, and the lowest quartiles indicated. 
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Host-driven selection of NM67 "survivors". The clearing or delayed growth of 
NM67 in the tissue cages, points to a decreased virulence of the teicoplanin 
resistant mutant. The surviving population that emerged from NM67 may 
consequently represent the selection and outgrowth of a variant or mutant 
subpopulation from NM67. Cells isolated on days 1 and 8 post infection were 
therefore analysed for host-induced changes in their phenotype and gene 
expression.  
 
Teicoplanin resistance. Teicoplanin MICs of NM67 isolates dropped to a 
median of 48 !g/ml after one day in the tissue cages, and then decreased further 
to median values of 0.36 !g/ml and 0.5 !g/ml on days 5 and 8, respectively. This 
was well below the MICs of SA113 isolates, which remained at a constant 2 
!g/ml throughout the 8 days. The survivors of NM67 collected from tissue cages 
after eight days showed a heterogeneous resistance profile, but the majority of 
the cells had become hypersusceptible compared to SA113 (Fig. 4).  
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Figure 4. Teicoplanin resistance profiles after passage in tissue cages. 
Median values of population analysis profiles on increasing concentrations of 
teicoplanin for strain SA113 and NM67 isolated from tissue cages on days 1 and 
8. Filled triangles with solid line, strain NM67 on day 1 (n = 5); filled triangles with 
dotted line, strain NM67 on day 8 (n = 4); filled circles with solid line, strain 
SA113 on day 1 (n = 4); and filled circles with dotted line, SA113 on day 8 
(n = 4). 
 
 
 
Cell size. On day 1 of infection, cell size and cell wall thicknesses measurements 
of SA113 and NM67 tissue cage isolates were similar to the original in vitro 
values; NM67 cells were still significantly smaller with thicker cell walls than 
SA113 (Fig. 5). After eight days of infection, the cell walls of NM67 survivors 
became thinner and their cell diameters increased, whereas both overall cell-wall 
thickness and cytoplasm diameter did not change in wildtype SA113, (Fig. 5A 
and B). On day 8, the cell wall of NM67 was still slightly thicker (p < 0.05) than 
that of SA113, however the cytoplasm diameter was now similar in both strains. 
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Figure 5.  Transmission electron microscopy of SA113 and NM67. A) 
diameter of cytoplasm and cell wall thickness of SA113 and NM67 ex vivo on 
days 1 and 8 of infection. Bars show the average cytoplasm diameter and cell 
wall thickness in nm. Mean values from at least 20 electron microscopy pictures, 
made from bacteria which were harvested from 3 mice infected with either NM67 
or SA113 are shown. **, p < 0.01 NM67 vs. SA113 cell wall thickness on day 1; 
***, p < 0.001 NM67 vs. SA113 cytoplasm diameter on day 1; *, p < 0.05 NM67 
vs. SA113 cell wall thickness on day 8. B) representative TEM pictures of SA113 
(A,B) and NM67 (C,D) on days 1 (left) and 8 (right). Scale bars in the bottom right 
hand corners of the pictures correspond to 50 nm. 
 
 
 
N-acetylglucosamine incorporation and turnover. The incorporation of 14C-N-
acetylglucosamine in cells isolated from TCF was significantly (4.5 fold, p < 0.05) 
higher in NM67 than in SA113 on day 1. Incorporation decreased with time 
during infection in both strains. However, on day 8 the surviving NM67 cells still 
showed a higher incorporation rate (2.5 fold, p < 0.05) than SA113 (Fig. 6A). 
Surprisingly, cell wall turnover remained unchanged, with no significant 
differences between SA113 and NM67 in the release rates of 14C-labelled N-
acetylglucosamine into the culture supernatant after passage in the tissue cages 
(data not shown).  
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Growth rate and hemolysin production. The minimum doubling time of NM67 
(37.6 ± 1.4 min) decreased in the tissue cage survivors to mean values of 36.2 ± 
1.6 min after day 1 and 32.5 ± 3.6 min after day 8. Meanwhile the minimum 
doubling time of SA113 (25.7 ± 1.7 min) remained relatively stable, with 
recovered isolates exhibiting mean minimal doubling times of 26.0 ± 0.6 min and 
25.7 ± 1.0 min, on days 1 and 8 of infection, respectively. Hemolysin production, 
which was undetectable in NM67 in vitro, was partially restored in the NM67 
survivors isolated on day 8 of infection. While, hemolytic activities of SA113 
supernatants remained relatively stable during the course of infection (Fig. 6B). 
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Figure 6. Changes in 14C-N-acetylglucosamine incorporation and 
hemolysis. 14C-N-acetylglucosamine incorporation. Filled circle solid line, 
SA113, and filled triangle solid line, NM67, on day 1; filled circle dotted line, 
SA113, and filled triangle dotted line NM67, on day 8 after infection. Median 
values from four cages measured, and lowest quartiles are indicated for each 
group. ANOVA for repeated measures p < 0.05 (*) NM67 vs. SA113 on days 1 
and 8, respectively. B) Hemolysis zones on sheep blood agar. One 
representative TCF isolate is shown for each strain from days 1 and 8. 
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Cell wall properties. Spontaneous autolysis rates for NM67 and SA113 isolates 
remained similar over the 8 day infection period (data not shown). Zymography, 
performed on SA113 and NM67 isolates collected during infection, showed no 
alterations in abundances of the 62-kDa amidase, the 50-kDa N-
acetylglucosaminidase and of an undefined 36-kDa enzyme band in SA113 and 
NM67 isolates (data not shown). SA113 and NM67 were both similarly 
lysostaphin susceptible, as were all isolates recovered from the tissue cages 
(data not shown). Proportions of peptidoglycan monomers and multimers were 
similar, with peptidoglycan crosslinking degrees of 65.9% on day 1 and 66.1% on 
day 8 of infection for NM67, and 68.5% and 71.2% on days 1 and 8 of infection, 
respectively, for SA113. Therefore, physical qualities of the cell wall, such as 
resistance to osmotic stress, peptidoglycan crosslinking, susceptibility to 
lysostaphin, and autolysin banding pattern were very similar in wildtype and 
mutant and did not change remarkably during infection.  
 
Northern analysis of ex vivo isolates. In ex vivo SA113 isolates, the 
transcription levels of all ORFs analysed remained the same as the parent. 
Transcription levels in the ex vivo NM67 survivors were more variable. For spa, 
SA1007 and geh, transcription levels had increased again after passage in vivo, 
with the signals approaching wildtype levels again by day 1 of infection. 
However, transcription of sbi and opp-1A remained low in the NM67 survivors 
(Fig. 2B).  
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DISCUSSION 
The fitness cost of glycopeptide intermediate resistance in S. aureus has been 
evidenced in several studies by the decreasing growth rates of resistant strains 
and correlated in several cases with increases in cell wall thickness (42). This 
fitness burden, imposed by the accommodation of gross alterations in cell-wall 
morphology, is thought to account for the widely observed instability of the 
resistance phenotype. However, it has also been previously reported that 
conditions in a tissue cage infection model promoted the emergence of 
teicoplanin intermediate resistant mutants in the absence of teicoplanin pressure 
(56), suggesting that certain in vivo conditions favored the development, and 
thereby potentially the maintenance, of a teicoplanin resistance phenotype.  
Here we assed the fitness of the in vitro selected teicoplanin-resistant strain 
NM67 in a murine tissue cage model. Although the MIC for NM67 was above the 
teicoplanin break point for intermediate level resistance (25), we define NM67 as 
being glycopeptide intermediate resistant because of the genetic basis of its 
resistance mechanism, which is distinct from the van gene based resistance of 
clinical VRSA (11). GISA phenotypes and accompanying genetic alterations are 
known to vary from strain to strain, therefore not all GISA isolates share identical 
characteristics. NM67 did however show several typical GISA phenotypes such 
as decreased growth rate, increased cell wall thickness, and enhanced N-
acetylglucosamine uptake compared to its isogenic, susceptible parent. The 
tissue cage is a closed in vivo system, where neither bacteria nor attracted 
leukocytes can escape. The balance is in favor of bacterial survival, since 
phagocytes in tissue cage fluid show a decreased phagocytic and bactericidal 
activity compared to blood granulocytes (61). This particular situation reflects 
infection of an orthopedic implant, which explains why such low numbers of wild 
type S. aureus can cause a chronic persistent infection in the mice (31).  
In contrast to the parent strain, which replicated over the eight day period, and 
elicited bacterial load-dependent MIP-2 release, leukocyte infiltration and 
reduction of leucocyte viability; the teicoplanin resistant mutant was either 
immediately cleared from the tissue cages or began to lose viability then 
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recovered and started to grow after two days. The clearing or delayed growth of 
NM67 strongly suggested that the original teicoplanin resistant NM67 had lost its 
ability to cause a persistent infection, and was actively cleared in the tissue 
cages, while the survivors appeared to have regained wildtype virulence. The 
survivors had however also become hypersusceptible to teicoplanin, with MICs 
approximately four-fold less than the susceptible wildtype SA113. 
Characteristics of the reemerging NM67 survivors, such as their higher growth 
rate, the conversion to teicoplanin hypersusceptibility, their partial loss of the 
thickened cell wall paired with a reduction in the high N-acetylglucosamine 
incorporation rate, and the restitution of transcription of some of the 
downregulated virulence determinants, suggested that the survivors were 
phenotypic revertants of NM67, which arose by forward mutation, since not all 
wildtype characteristics had been restored. Similar forward mutations producing 
susceptible variants with slightly altered phenotypes have been observed earlier 
(13, 43).  
Despite maintaining a slightly thicker cell wall and higher N-acetylglucosamine 
uptake, NM67 survivors isolated on day 8 had lower teicoplanin MICs than 
SA113 isolates. Interestingly, resistance profiles of the wild-type SA113 remained 
relatively stable over the 8 day period; spontaneously resistant mutants did not 
arise as had been described earlier in a similar rat tissue cage infection model 
(56). Several factors may explain the absence of such spontaneous high 
resistant mutants in our model. Teicoplanin-resistant mutants were observed in 
the rat model as late as three weeks after infection; and were stable only when 
cultured continuously on teicoplanin-containing agar (56), while our study 
covered just the 8 days needed to reach the maximal numbers of CFU in the 
murine TC model. Also, we used a susceptible strain (MSSA), while the previous 
study used a multiresistant, clinical methicillin resistant (MRSA) isolate. The 
NCTC8325 strain lineage used in this study has no functional IS elements (53), 
whearas clinical multiresistant MRSA isolates may carry active IS elements, and 
thus have additional means to form glycopeptide resistant mutants by 
rearrangements and movement of the IS elements. IS256 transposition was 
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shown to facilitate mutations contributing to resistance levels in a clinical GISA 
isolate (34).  
Altered autolytic properties are sometimes observed in glycopeptide resistant 
strains (28, 59). However, neither cell wall crosslinking and turnover, nor the 
accessibility of the lysostaphin target, were affected by teicoplanin resistance in 
our in vitro selected strain. Here, glycopeptide resistance seemed to be mainly 
characterized by the thickened cell wall, although microarray analysis did not 
detect any significant upregulation of ORFs or any transcriptional changes that 
might account for these phenotypes, such as transcriptional alterations that have 
been described for other GISA strains (12, 33, 37). The microarray performed 
here is unlikely to reflect all transcriptional changes that occurred during the 
resistance development of NM67 as it was performed on cultures harvested at a 
single time point during in vitro growth and should therefore be regarded as a 
snap shot of some of the transcriptional changes that occurred during resistance 
formation. More detailed transcriptional analyses would be required to obtain a 
global picture of the differences between these strains.  
Altered virulence factor expression has been previously described in other GISA 
strains; spa transcription was decreased in Mu50 (33) and fibronectin binding 
protein production decreased in strain 14-4 (44). The decreased in vivo survival 
of NM67 may have been predicted by the gradual turning down of gene 
expression of virulence-associated genes as increased resistance was selected. 
It is likely that the downregulation of genes involved in biofilm formation, lipase, 
haemolysin and secretory antigen production and evasion of host immune 
responses, contributed to the poor survival of NM67 in vivo. The downregulation 
of virulence genes was probably a consequence of, but unlikely to be the cause 
of increased teicoplanin resistance.     
Transcription of some of the virulence associated genes was partially restored 
upon loss of the resistance phenotype in the in vivo selected survivors. This 
possible link between resistance profile and the transcription of virulence genes 
may be one explanation for why the resistance phenotype was lost so rapidly in 
the tissue cages that did not clear the teicoplanin-resistant bacteria. In these 
 
 
60 
cases the mutation(s) causing reversion of resistance and restoration of virulence 
gene expression must have occurred before the bacteria were cleared.  
In conclusion, intrinsic glycopeptide resistance acquisition can impose a fitness 
burden on S. aureus, creating selection pressure for the loss of the resistance 
phenotype in the absence of glycopeptides. In this study, the glycopeptide 
resistance level of NM67 gradually decreased upon in vitro culture in 
glycopeptide-free media; however, in vivo, in the presence of the host defense 
system, resistance was lost extremely rapidly due to the elimination of the 
resistant strain and subsequent selection for fitter, susceptible variants. The link 
between resistance acquisition and the decreased expression of virulence 
associated genes is likely to contribute to the strong selection for clearance of the 
resistant strain in vivo. It is also possible that the decreased growth rate, which 
accompanied the high level resistance, had also contributed to the poor in vivo 
survival of NM67. Compensatory mutations leading to decreased cell wall 
thickness indicate that metabolism reverts to normal, with the concomitant 
increase in virulence factor production indicating that the easiest way to restore 
fitness and virulence is at the expense of resistance.  
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ABSTRACT 
Clinical studies comparing the virulence of MRSA and MSSA strains, which 
cause sepsis, are hampered by confounding factors in patients. We used a 
mouse sepsis model a) to compare mortality of the two prevalent pandemic 
SCCmec IV MRSA clones in France (Lyon clone MRSA ST8 and a ST5 clone) 
and of MSSA with variable genetic background, which are prevalent in France in 
causing blood stream infections, b) to understand the contribution of SCCmec 
and of the two different sequence types ST5 and ST8 to outcome. All 44 isolates 
(10 MRSA ST8, 8 MSSA ST8, 8 MRSA ST5, 8 MSSA ST5 and 10 MSSA var. 
ST) were characterized by MLST, agr, spa and capsule typing, by measuring in 
vitro doubling time and resistance, toxin genes and proteins, and adhesin gene 
content. Infection with MRSA ST8 isolates caused a slightly, infection with ST5 
isolates a significantly higher mortality than infection with MSSA expressing 
variable ST (48 vs. 29%, ns and 70 vs. 29%, p<0.001). However, the same 10 
MRSA ST8 isolates caused a lower mortality than clonal MSSA ST8, (48 vs. 
73%, P <0.001). This was not related to the presence of SCCmec, since for 
MRSA of ST5, mortality was similar as that induced by MSSA ST5 (79 vs. 59%, 
ns). Despite the same genetic background individual clonal MRSA isolates had 
heterogeneous virulence properties. No specific virulence factor determined in 
vitro, was found related to mortality in mice. In conclusion, in a bacteraemic 
model, lethality varied with the ST in the presence or absence of SCCmec. 
Within a ST, clonality was not associated with a homogenous outcome in the 
mouse model. 
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INTRODUCTION  
S. aureus is a pathogen expressing multiple virulence factors such as adhesins, 
toxins and immune evasion molecules that enable the bacteria to induce a wide 
variety of infections. Hospital-acquired methicillin-resistant S. aureus (MRSA) 
arose in 1961 through the acquisition of the SCCmec element and became one 
of the most frequent pathogens responsible for hospital-acquired infections 
worldwide, particularly in intensive care units (ICU). Molecular characterization by 
multilocus sequence typing (MLST) of clinical MRSA isolates in a given area 
revealed that most of them are genetically related, i.e they share the same 
sequence type (ST) which belongs to one of the five major clonal complexes 
(CC). In France, we recently described and genetically characterized the 
healthcare-associated MRSA isolates. The major clone, named Lyon clone, 
shares ST8 that belongs to CC8, and a minor one, which is related to the New-
York-Japan clone and is spreading since a few years, shares ST5 that belongs to 
CC5  (6). 
Differences in pathogenicity and virulence among MRSA and MSSA isolates may 
exist but remained an unresolved question. Studies of MRSA virulence in human 
suggest a greater burden for MRSA infections, in term of length of hospitalization 
and mortality rate, but these studies are impaired by multiple confounding 
factors. First, differences in patient populations, that have different co-morbid 
conditions, and differences in therapeutic options that are more or less 
bactericidal, limit conclusions about a putative increased virulence associated 
with methicillin resistance. Second, each pandemic MRSA clone may have 
specific virulence properties, as has been demonstrated for the pandemic MRSA 
clone in Brazil (CC8, ST239), which has an enhanced ability to adhere and 
invade epithelial cells in vitro in comparison with sporadic MRSA isolates (1). 
The aims of this study were to: (i) compare the mortality rate induced by isolates 
belonging to pandemic MRSA clones in France with mortality caused by MSSA 
isolates in an inbred mouse model of sepsis, thus eliminating confounding factors 
associated with host variation and antimicrobial therapy; (ii) to investigate the 
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relationship between different virulence factors expressed by each S. aureus 
lineage and mouse mortality. 
 
 
 
74 
MATERIALS AND METHODS 
S. aureus isolates. 
We used MRSA isolates that allowed us to describe the major MRSA clone in our 
hospital. During a survey in ICUs of Edouard Herriot Hospital (a 1100-bed 
university hospital located in Lyon, France) we collected 17 MRSA isolates 
responsible for bloodstream infections and characterized two different MRSA 
clones (8). A major one, called Lyon clone (13 of the 17 isolates shared agr type 
1 allele, ST8, CC8, spa type t008 or relatives and were positive for the sea 
gene), and a minor one related to the New-York-Japan clone (3 of the 17 isolates 
shared agr type 2 allele, ST5, CC5, spa type t002 or relatives, SCCmec type IV 
and were positive for the tst gene and the egc locus). Epidemiological studies 
(unpublished) revealed that the Lyon clone was the predominant MRSA clone in 
France whereas the ST5 MRSA clone was emergent and spreading throughout 
France since few years. We randomly selected for the analysis 10 of the 13 
MRSA ST8 Lyon clone isolates, the three MRSA ST5 positive for the tst gene 
and the egc locus, and 10 of the 19 MSSA isolates with various STs (one ST8, 
four ST15, one ST45, one ST97, one ST217, one ST463 and one ST465) also 
responsible for bloodstream infection in the same area in the same period of 
time. To analyze the effect of the SCCmec cassette and the effect of the genetic 
background on the virulence, we completed the first strain selection by adding 
eight MSSA ST8 and eight ST5 isolates. These isolates were also from 
bloodstream infections and were collected by the National Center for 
Staphylococci located in Lyon, France, either during a national survey (in 2006-
2007) or spontaneously referred to the Center (in the 2003-2007 period). Five 
MRSA ST5 isolates were also taken from the national survey to complete the first 
selection of three MRSA ST5. Finally, a total of 44 S. aureus isolates were 
included in the study and grouped as follows: 10 MRSA ST8, 10 MSSA with 
variable ST (MSSA var. ST), 8 MSSA ST8, 8 MRSA ST5 and MSSA ST5. MRSA 
ST8 and MSSA ST8 were positive for the sea gene; MRSA ST5 and MSSA ST5 
isolates were positive for the tst gene and the egc locus. 
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Characterization of the genetic background and virulence factors.  
All strains were characterized by MLST, spa typing and accessory gene regulator 
(agr) allele typing (1-4) as previously described. Capsular typing was based on 
serotyping and PCR as previously described (21). Each isolate was genetically 
characterized by adhesin gene profiling (bbp, cna, eno, ebpS, clfA, clfB, fnbA and 
fnbB), toxin gene content (tst; staphylococcal enterotoxins and enterotoxins-like 
sea, seb, sec, sed, see, seh, selk, sell, selm, selo, selp, selq, selr). Positive 
isolates for selm and selo were considered to be also positive for the egc locus, 
as these genes belong to the egc operon. Delta-toxin production was determined 
in an agar plate assay testing synergy with a beta-toxin reference strain as 
previously described; isolates without delta-toxin production were considered to 
have dysfunction of the locus agr (18). Production of alpha-toxin was determined 
by incubating the strains overnight on sheep blood agar plates at 37°C. 
Superantigen expression was measured by using the RIDASCREEN SET A, B, 
C, D and E (R-Biopharm AG, Darmstadt, Germany). Finally, bacterial doubling 
time was determined as previously described with minor modifications (7). 
Overnight cultures were diluted 1:100 in 5 ml of BHI medium and grown for 3 h at 
37°C with shaking (180 rpm). These cultures were seeded at 1:100 dilution and a 
1:4 culture-to-flask ratio, then incubated at 37°C and 180 rpm for 4 h. Optical 
density (OD) was measured every 30 min for 4 h. Values were converted into 
log2 values and the doubling time was calculated as the reciprocal of the slope. 
 
Determination of the virulence in mice sepsis model. 
C57BL/6 mice were kept in specific-pathogen-free conditions in the Animal 
House of the Department of Research, University Hospital Basel, Switzerland 
and all experiments were performed according to Swiss veterinary law. Before 
intravenous challenge, S. aureus isolates were grown freshly from frozen stock 
cultures (-70°C) prepared using the Microbank system (Pro Lab Microbank 
Bacterial Preservation System Green, Basel, CH). One cryoculture bead per 
strain was incubated in 1 ml of brain-heart infusion (BHI) broth (BBL Becton 
Dickinson, Maryland) for 7 h at 37°C. Cultures were then diluted 1:100 in 5 ml of 
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BHI and incubated overnight at 37°C. The bacteria were then centrifuged at 
4000 g for 10 min, and the pellet was washed twice and resuspended in pyrogen-
free 0.9% NaCl before use. Female 6-8 weeks old C57BL/6 mice were injected 
with MRSA and MSSA inocula ranging from 5.1 x 107 to 1.4 x 108 CFU (median) 
in a volume of 200 !l via the caudal vein. Control mice were injected with 200 !l 
0.9% NaCl. Inocula for the different groups of strains were not significantly 
different: For MRSA ST8 the median inoculum was 1.4 x 108 CFU; for MSSA var. 
ST it was 6.5 x 107 CFU; for MSSA ST8 it was 6.8 x 107 CFU; for MRSA ST5 it 
was 6.8 x 107 CFU and for MSSA ST5 it was 5.1 x 107 CFU; control mice were 
injected with 200 !l of 0.9% saline. Weight change and disease severity were 
determined on day 1 to 9 after infection. Disease severity was assessed by a 
scoring system (0, normal activity; 1, trembling, weakness; 2, piloerection, 
decreased activity; 3, strongly decreased activity; 4, no movement). The mice 
were killed by intraperitoneal injection of 100 mg/kg pentobarbital (Abbott 
Laboratories) when they reached a score of 4 and surviving mice were sacrificed 
on day 9 after infection. At least 4 mice were used per group. 
 
Data analysis. Data were analyzed with Graph Pad Prism 4 software. P values 
< 0.05 were considered to denote statistical significance. Survival differences 
between mice challenged with the different groups of strains were analyzed 
during the infection process with the log rank test and a Kaplan-Meier survival 
curve. Overall mortality between groups was compared by Chi-square 
contingency test.  
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RESULTS 
 
Virulence properties in the murine sepsis model, and comparison between 
groups of strains 
 
Comparison of MRSA ST8 and MRSA ST5 groups with MSSA var. ST  
The collection of MRSA ST8 and ST5 as well as that of MSSA var. ST isolates 
simulate the distribution of S. aureus in clinical settings in French ICUs. The 
infection of mice with these strains revealed a trend to a higher mortality for the 
MRSA ST8 group in comparison with the MSSA var. ST group, both by 
comparing survival curves and by comparing the overall mortality occurred during 
infection (Fig. 1A). These differences were significant after including further 48 
and 41 mice that were infected with a wider range of inocula of MRSA ST8 and 
MSSA var. ST respectively (P < 0.011). The overall mortality induced by the 
MRSA ST5 group was extremely high (79%), it was significantly higher than that 
induced by the MSSA var. ST group (29%) and occurred early between day 1 
and 4 of sepsis (Fig. 1B).  
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Fig1. Percentage survival of mice infected with MRSA and MSSA isolates  
A) Survival of 44 and 55 mice infected with 10 MRSA ST8 isolates (closed 
circles; 1.4 x 108 CFU/mouse) and 10 MSSA isolates of var. ST (open triangles; 
6.5 x 107 CFU/mouse) respectively (log rank test, P = 0.072). B) Survival of 42 
and 55 mice infected with 10 MRSA ST5 (closed squares; 6.8 x 107 CFU) and 10 
MSSA isolates of var. ST (opentriangles; 6.5 x 107 CFU) respectively (log rank 
test, P < 0.0001). " 4 mice were infected with each strain. Statistics of overall 
mortality was determined by Chi-square test. 
 
 
Effect of the SCCmec cassette on virulence in ST5 and ST8 lineages 
The comparison of clonal MRSA with variable MSSA did not allow any 
conclusion on the role of SCCmec for virulence. Therefore outcome of sepsis 
was compared in C57BL/6 mice infected with MRSA or MSSA from the same ST. 
In this comparison the MRSA ST8 group induced a lower mortality than the 
MSSA ST8 group (Fig. 2A). Conversely, mortality with MRSA ST5 was higher 
than with the MSSA ST5 group, although the overall value in groups with ST5 
observed at day nine was not significantly different (Fig. 2B). 
Thus SCCmec had a variable influence upon outcome depending on the ST 
lineage. This was also confirmed by a comparative analysis of survival curves 
after infection with MRSA and MSSA of the two lineages. In MRSA, the ST5 
lineage, compared to the ST8 lineage, conferred a significantly higher mortality 
(Fig. 2C). In MSSA, the reverse was observed. ST8 conferred a higher mortality 
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compared with that of the ST5, although overall mortality was not significantly 
different (Fig. 2D).  
 
 
 
 
Fig. 2 Percentage survival of mice infected with MRSA and MSSA isolates  
A) Survival of 44 and 41 mice infected with 10 MRSA ST8 (closed circles; 
1.4 x 108 CFU) and 8 MSSA ST8 isolates (open circles; 6.8 x 107 CFU) 
respectively (P = 0.0012). B) Survival of 42 and 32 mice infected with 8 MRSA 
ST5 (closed squares; 6.8 x 107 CFU) and 8 MSSA ST5 (open squares; 5.1 x 107 
CFU) respectively (P < 0.001). C) Survival of 44 and 42 mice infected with 10 
MRSA ST8 (closed circles; 1.4 x 108 CFU) and 8 MRSA ST5 isolates (closed 
squares; 6.8 x 107 CFU) respectively (P < 0.0001). D) Survival of 41 and 32 mice 
infected with 8 MSSA ST8 (open circles; 6.8 x 107 CFU) and 8 MSSA ST5 (open 
squares; 5.1 x 107 CFU), respectively (P = 0.0059)." 4 mice were infected with 
each strain. Chi-square test was used to determine overall mortality.  
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Association between virulence factors, MRSA and MSSA, sequence type 
and mouse mortality  
 
Virulence factors of MRSA ST8 and MRSA ST5 and MSSA var. ST 
Isolates belonging to the MRSA ST8 and ST5 groups’ harbored capsular type 5, 
whereas four of the MSSA var. ST group expressed capsular type 5, the six 
remaining isolates had capsular type 8. Isolates belonging to the MRSA ST8 and 
ST5 groups harbored genes encoding SEA and TSST-1, respectively, whereas 
none of the MSSA var. ST isolates harbored any of these genes. Finally, the 
group of MRSA ST8 showed a slightly slower in vitro growth than the group of 
MSSA var. ST with a mean doubling time of 34.60 ± 2.70 min compared to 29.20 
± 1.15 min (P = 0.08). Doubling times of isolates belonging to the MRSA ST5 
group were similar with 30.00 ± 3.88 min (P = 0.83). 
 
 
Mouse mortality induced by individual isolates of ST5 and ST8 lineages 
Three of the 10 isolates belonging to the MRSA ST8 group were never fatal 
whereas five were fatal for 80 to 100% of the mice. As shown in Fig. 3, no 
specific virulence factor was able to discriminate between lethal and non-lethal 
isolates. Similarly, two isolates belonging to the MSSA ST5 group were never 
fatal and did not lack any particular adhesin or toxin, which could explain the 
reduced virulence (Fig. 4).  
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Fig3 
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Fig. 4 
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DISCUSSION 
In this study we found that, MRSA isolates belonging to the Lyon clone, 
expressing ST8, which is the main clonal population of MRSA prevailing in a 
large French hospital, collectively exhibited a lower virulence in a murine sepsis 
model than MSSA isolates of the same ST8. This observation was mitigated in 
the comparison of MRSA ST8 and MSSA with variable ST. We further found that 
lower virulence of MRSA was not due to the acquisition of SCCmec per se, since 
MRSA ST5 showed virulence as strong as MSSA ST8. Finally, individual clones 
of MRSA or MSSA either ST5 or ST8 showed a variable virulence, and no 
relationship between known virulence factors and lethality in the sepsis model 
was found. 
The Lyon clone MRSA isolates showed a heterogeneous low level of resistance 
to oxacillin. Acquisition of the SCCmec type I element has previously been 
shown to slow the S. aureus doubling time in vitro (7). However, in the present 
study, we found that clonal MRSA and MSSA isolates of either ST 8 or ST 5 had 
similar doubling times, possibly indicating that a potential initial fitness burden 
(12) due to SCCmec acquisition was overcome by compensatory mutations, or 
that only clones retaining rapid growth survived (2, 13). 
In the sepsis model the MRSA ST8 clone isolates killed less mice than the MSSA 
ST8 isolates. This observation supports the previous results of Mizobuchi et al., 
who compared the virulence of 13 highly resistant MRSA and 7 MSSA isolated 
from patients with various clinical syndromes (14) and found that MRSA were 
less virulent than MSSA; however, it is noteworthy that the strains were not 
genetically characterized. Peacock et al. found that a strain belonging to an 
epidemic MRSA clone showed similar lethality to three clinically significant MSSA 
strains after intraperitoneal or intravenous inoculation to mice (17). Our 
comparative study of MRSA and MSSA infection in mice is strengthened by the 
genetic homogeneity of the MSSA isolates. Our findings highlight that clonal 
isolates have to be compared when the effect of SCCmec upon virulence is to be 
identified. Indeed, in our initial series in which lethality induced by MRSA ST8 
was compared to that induced by the genetically variable MSSA isolates an 
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apparently higher virulence of MRSA ST8 was observed.  Nevertheless the 
acquisition of SCCmec type IV per se is not associated with a loss of virulence, 
since our MRSA isolates ST5 were as virulent as MSSA ST8.  
When investigating virulence factors, which could contribute to death, 
surprisingly, MRSA and MSSA isolates with a homogenous genetic background 
to the level of our present knowledge had a heterogeneous outcome. Capsular 
polysaccharides contribute to staphylococcal virulence. Most clinical S. aureus 
isolates have serotype 5 (CP5) or serotype 8 (CP8) capsules. By comparing the 
biological activities of isogenic mutants with CP5, CP8 or no capsule in a mouse 
model, Watts et al. showed that CP5-positive strains were more virulent than 
both CP8-positive strains and CP-negative strains (22). We found no correlation 
between CP5 and mouse lethality. Among the MRSA tested here, all of which 
were CP5-positive, three strains were non-lethal for mice.  
When interpreting our mouse lethality data it is important to remember that mice 
are susceptible to certain virulence determinants (hemolysin, leukocidin, etc.), 
but are less susceptible than men to superantigenic toxins. Mouse susceptibility 
to these toxins can be enhanced by D-galactosamine administration (4, 19). We 
had previously assumed that SEA was involved in the pathogenesis of S. aureus 
septic shock, as we had found that sea was more frequent in blood isolates from 
patients with septic shock than from patients without septic shock (9). However, 
all 10 Lyon clone isolates tested here harbored the sea gene and produced SEA 
in vitro, but three isolates were non lethal for mice, suggesting that SEA is not a 
major MRSA virulence factor. In contrast, Nilsson et al. demonstrated that 
vaccination with genetically modified SEA lacking superantigenic properties 
conferred protection in a non-sensitized murine sepsis model induced by an 
S. aureus strain expressing sea in vitro (16). The sea gene has been detected in 
several pandemic MRSA clones (CC8 and CC30) (8). Recently, Diep et al. 
demonstrated that horizontal transfer of virulence genes such as sea was 
epidemiologically associated with the emergence of new virulent strains of both 
hospital- and community-acquired MRSA (5). It cannot be excluded that SEA 
was differentially expressed in vivo in lethal and non-lethal isolates.  
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Five of the 10 MRSA ST8 isolates tested here produced alpha-toxin and 
harbored genes encoding gamma-toxin. Alpha-toxin has been shown to cause 
epithelial damage in a model of corneal and tracheal staphylococcal infection (3, 
10). In addition, in a rat model of heart failure, alpha-toxin provoked coronary 
vasoconstriction and cardiodepression, both of which can occur in the course of 
sepsis (11). Gamma-toxin had a pro-inflammatory effect in a rabbit 
endophthalmitis model (20). However, only alpha- and gamma-toxin jointly 
promoted S. aureus virulence in a septic arthritis model (15). Thus, toxins may 
play an important role in local infection, whereas there is no firm evidence that 
alpha toxin or gamma-toxin are directly involved in septic shock.  
In conclusion, MRSA isolates of the Lyon clone expressed heterogeneous 
methicillin resistance and harbored heterogeneous intrinsic bacterial 
characteristics and virulence properties. This heterogeneity may be linked not 
only to one specific virulence factor, but to differences in global regulation or to 
single nucleotide polymorphisms not detected in our study. Lastly, whole genome 
sequencing of the clonal isolates with differing outcome will allow identifying the 
hitherto unknown genes responsible for high virulence. 
 
 
86 
Acknowledgements 
 
This work was supported by Swiss National Foundation grant 40-4940-106295/1 
to R.L. We thank Christine Courtier, Christine Gardon, Lys Mayor, Zarko Rajacic, 
Martine Rougier and Isabelle Verdier for technical assistance, and David Young 
for editorial assistance.  
 
 
87 
References:  
 
1. Amaral, M. M., L. R. Coelho, R. P. Flores, R. R. Souza, M. C. Silva-
Carvalho, L. A. Teixeira, B. T. Ferreira-Carvalho, and A. M. Figueiredo. 2005. 
The predominant variant of the Brazilian epidemic clonal complex of methicillin-
resistant Staphylococcus aureus has an enhanced ability to produce biofilm and 
to adhere to and invade airway epithelial cells. J Infect Dis 192:801-10. 
2. Andersson, D. I., and B. R. Levin. 1999. The biological cost of antibiotic 
resistance. Curr Opin Microbiol 2:489-93. 
3. Dajcs, J. J., B. A. Thibodeaux, D. O. Girgis, and R. J. O'Callaghan. 
2002. Corneal virulence of Staphylococcus aureus in an experimental model of 
keratitis. DNA Cell Biol 21:375-82. 
4. De Boer, M. L., W. W. Kum, L. T. Pang, and A. W. Chow. 1999. Co-
production of staphylococcal enterotoxin A with toxic shock syndrome toxin-1 
(TSST-1) enhances TSST-1 mediated mortality in a D-galactosamine sensitized 
mouse model of lethal shock. Microb Pathog 27:61-70. 
5. Diep, B. A., H. A. Carleton, R. F. Chang, G. F. Sensabaugh, and F. 
Perdreau-Remington. 2006. Roles of 34 virulence genes in the evolution of 
hospital- and community-associated strains of methicillin-resistant 
Staphylococcus aureus. J Infect Dis 193:1495-503. 
6. Durand, G., M. Bes, H. Meugnier, M. C. Enright, F. Forey, N. Liassine, 
A. Wenger, K. Kikuchi, G. Lina, F. Vandenesch, and J. Etienne. 2006. 
Detection of new methicillin-resistant Staphylococcus aureus clones containing 
the toxic shock syndrome toxin 1 gene responsible for hospital- and community-
acquired infections in France. J Clin Microbiol 44:847-53. 
7. Ender, M., N. McCallum, R. Adhikari, and B. Berger-Bachi. 2004. 
Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus 
aureus. Antimicrob Agents Chemother 48:2295-7. 
8. Ferry, T., M. Bes, O. Dauwalder, H. Meugnier, G. Lina, F. Forey, F. 
Vandenesch, and J. Etienne. 2006. Toxin gene content of the Lyon methicillin-
 
 
88 
resistant Staphylococcus aureus clone compared with that of other pandemic 
clones. J Clin Microbiol 44:2642-4. 
9. Ferry, T., T. Perpoint, F. Vandenesch, and J. Etienne. 2005. Virulence 
determinants in Staphylococcus aureus and their involvement in clinical 
syndromes. Curr Infect Dis Rep 7:420-8. 
10. Girgis, D. O., G. D. Sloop, J. M. Reed, and R. J. O'Callaghan. 2005. 
Effects of toxin production in a murine model of Staphylococcus aureus keratitis. 
Invest Ophthalmol Vis Sci 46:2064-70. 
11. Grandel, U., U. Sibelius, J. Schrickel, D. Schmidt, M. Buerke, L. Fink, 
E. Bournelis, M. Heep, K. Mayer, R. M. Bohle, W. Seeger, and F. 
Grimminger. 2001. Biosynthesis of constitutive nitric oxide synthase-derived 
nitric oxide attenuates coronary vasoconstriction and myocardial depression in a 
model of septic heart failure induced by Staphylococcus aureus alpha-toxin. Crit 
Care Med 29:1-7. 
12. Maisnier-Patin, S., and D. I. Andersson. 2004. Adaptation to the 
deleterious effects of antimicrobial drug resistance mutations by compensatory 
evolution. Res Microbiol 155:360-9. 
13. McCallum, N., H. Karauzum, R. Getzmann, M. Bischoff, P. 
Majcherczyk, B. Berger-Bachi, and R. Landmann. 2006. In vivo survival of 
teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin 
resistance. Antimicrob Agents Chemother 50:2352-60. 
14. Mizobuchi, S., J. Minami, F. Jin, O. Matsushita, and A. Okabe. 1994. 
Comparison of the virulence of methicillin-resistant and methicillin-sensitive 
Staphylococcus aureus. Microbiol Immunol 38:599-605. 
15. Nilsson, I. M., O. Hartford, T. Foster, and A. Tarkowski. 1999. Alpha-
toxin and gamma-toxin jointly promote Staphylococcus aureus virulence in 
murine septic arthritis. Infect Immun 67:1045-9. 
16. Nilsson, I. M., M. Verdrengh, R. G. Ulrich, S. Bavari, and A. Tarkowski. 
1999. Protection against Staphylococcus aureus sepsis by vaccination with 
recombinant staphylococcal enterotoxin A devoid of superantigenicity. J Infect 
Dis 180:1370-3. 
 
 
89 
17. Peacock, J. E., Jr., D. R. Moorman, R. P. Wenzel, and G. L. Mandell. 
1981. Methicillin-resistant Staphylococcus aureus: microbiologic characteristics, 
antimicrobial susceptibilities, and assessment of virulence of an epidemic strain. 
J Infect Dis 144:575-82. 
18. Sakoulas, G., G. M. Eliopoulos, R. C. Moellering, Jr., C. Wennersten, 
L. Venkataraman, R. P. Novick, and H. S. Gold. 2002. Accessory gene 
regulator (agr) locus in geographically diverse Staphylococcus aureus isolates 
with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 
46:1492-502. 
19. Schwan, W. R., M. H. Langhorne, H. D. Ritchie, and C. K. Stover. 
2003. Loss of hemolysin expression in Staphylococcus aureus agr mutants 
correlates with selective survival during mixed infections in murine abscesses 
and wounds. FEMS Immunol Med Microbiol 38:23-8. 
20. Supersac, G., Y. Piemont, M. Kubina, G. Prevost, and T. J. Foster. 
1998. Assessment of the role of gamma-toxin in experimental endophthalmitis 
using a hlg-deficient mutant of Staphylococcus aureus. Microb Pathog 24:241-
51. 
21. Verdier, I., G. Durand, M. Bes, K. L. Taylor, G. Lina, F. Vandenesch, A. 
I. Fattom, and J. Etienne. 2007. Identification of the Capsular Polysaccharides 
in Staphylococcus aureus Clinical Isolates by PCR and Agglutination Tests. J 
Clin Microbiol 45:725-9. 
22. Watts, A., D. Ke, Q. Wang, A. Pillay, A. Nicholson-Weller, and J. C. 
Lee. 2005. Staphylococcus aureus strains that express serotype 5 or serotype 8 
capsular polysaccharides differ in virulence. Infect Immun 73:3502-11. 
 
 
 
 
90 
 
 
Chapter III 
 
 
HOST-PATHOGEN INTERACTIONS 
USING CLONALLY RELATED METHICILLIN-RESISTANT 
STAPHYLOCOCCUS AUREUS ISOLATES 
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INTRODUCTION 
In the third part of my thesis, I investigated the phenotypic properties of, and 
immune response to clonal MRSA isolates, which elicited a variable outcome in 
the murine sepsis model. Since we could not attribute their variable lethality to 
toxins or adhesin genes, we searched for a confirmatory typing method and 
applied MLVA. Further we investigated other pathogen properties, which would 
help explain their variable in vivo behavior, such as clumping. We also 
investigated chemotaxis, susceptibility to PMN killing, apoptosis of PMN and T, B 
and dendritic cell response in liver and spleen hoping that host reaction to lethal 
and non-lethal isolates would be different and that through the different host 
reactions we would be able to reveal virulence factors relevant for the lethal 
effects observed in the mouse model.  
The inter-human dissemination and invasion in human infection of S. aureus is 
relying on the expression of microbial surface components recognizing adhesive 
matrix molecules (MSCRAMMs) in the host, such as ClfA/B, FnbP and Cna.  
Role of ClfA was studied, since it is known to mediate clumping of bacteria in the 
presence of fibrinogen in vitro (8), due to the dimeric structure of fibrinogen 
enabling two ClfA molecules to bind simultaneously. The interactions occur 
between the N-terminal A domain of ClfA and the gamma chains of fibrinogen 
(15). Furthermore fibrinogen can serve as a bridging molecule to attach to host 
cells (14). Bacterial clumping, often found in abscesses, is probably a 
mechanism to make bacteria more resistant to host defense, such as 
opsonization and phagocytosis (10, 11). Moreillon et al. showed a S. aureus clfA-
defective mutant had decreased adherence in vitro and also a decreased 
virulence in a rat endocarditis model (17).  
Next, chemotaxis of PMN was investigated since S. aureus is known to secrete 
proteins that thwart PMN recruitment. The chemotaxis inhibitory protein (CHIPS), 
a 14.1 kDa protein, is known to inhibit chemotaxis by binding to formyl peptide 
(FPR) and C5a receptor and thus competing out their physiological ligands (3). 
The extracellular adherence protein (Eap), a 60 kDa protein inhibits leukocyte 
chemotaxis by binding directly to host adhesive proteins, like ICAM-1, expressed 
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on endothelial and epithelial cells, and thus hinders the interaction with 
leukocytes necessary for diapadesis and extravasation (2).  
Since several groups demonstrated, that upon internalization S. aureus secretes 
certain pore-forming toxins that lead to the activation of caspases of the host 
cells and to apoptosis, we measured apoptosis in vitro (6, 16, 24). PMN undergo 
constantly spontaneous apoptosis and signal macrophages to recognize and 
remove them, an important process to prevent host tissue damage and 
inflammation (20). This spontaneous apoptosis, was shown to be accelerated 
upon uptake of S. aureus (12, 13).  
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MATERIALS AND METHODS  
Preparation of bacteria and supernatants 
Bacteria were grown freshly from frozen stock cultures (-70°C) prepared using 
the Microbank system (Pro Lab Microbank Bacterial Preservation System Green, 
Basel, CH). One cryoculture bead per strain was incubated in 1 ml of brain-heart 
infusion (BHI) broth (BBL Becton Dickinson, Maryland) for 7 h at 37°C. Cultures 
were then diluted 1:100 in 5 ml of BHI and incubated overnight at 37°C. The 
bacteria were then centrifuged at 4000 g for 10 min, and depending on further 
usage, the pellets were taken up immediately or after washing twice in 0.9% 
NaCl.  
For sepsis, killing, and apoptosis experiments, the pellet was washed twice and 
re-suspended in pyrogen-free 0.9% NaCl before use.  
For chemotaxis, bacteria were grown from cryoculture beads as described 
above, but instead of BHI, synthetic medium was used. The overnight cultures 
were centrifuged at 4000 g for 10 min, the supernatants (SUP) were filtered 
through 0.22 !m filters (Millex- MP, Millipore) and dialyzed against PBS 
(Phosphate Buffered Saline, Laboratorium Dr. Bichsel AG, Interlaken) using 3.5 
kDa membrane tubings (Spectra/Por, Spectrum Laboratories, Inc., Canada). 
Aliquots of dialyzed and non-dialyzed supernatants were frozen at –70°C.  
For adhesion and clumping assays, bacteria were grown from cryoculture beads 
as described above and were washed twice in PBS. To yield a concentration of 
about 5 x 108 CFU, the pellet was taken up in 2 ml of PBS.  
For the peritonitis model, bacteria were grown from cryoculture beads as 
described above, but instead of BHI, Iscove’s modified Dulbecco’s medium 
(IMDM) without phenol red was used (GIBCO, Invitrogen).  
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Multi-locus variable–number tandem repeat analysis (MLVA) 
MLVA was performed as described previously (19). MW2 was used as a 
reference strain. The primers used for the assay are described below.  
 
mecA  (F-CATTGATCGCAACGTTCAATTT)  
(R-TGGTCTTTCTGCATTCCTGGA);  
sspA  (F-ATCMATTTYGCMAAYGATGACCA) 
(R-TTGTCTGAATTATTGTTATCGCC);  
spa   (F-AGCACCAAAAGAGGAAGACAA) 
(R-GTTTAACGACATGTACTCCGT); 
sdrCDE (F-TTACGGATCATGATGATTTCA) 
(R-CAYTACCTGTTTCTGGTAATGCTT);  
clfB  (F-ATGGTGATTCAGCAGTAAATCC) 
(R-CATTATTTGGTGGTGTAACTC TT);  
clfA  (F-GATTCTGACCCAGGTTCAGA) 
(R-CTGTATCTGGTAATGGTTCTTT);  
fnBP  (F-GGTCAAGCRCAAGGACCART) 
(R-AATAATCCGCCGAACAACAT);  
sasA  (F-TTGGAACATTCGAATATACAGAGT) 
(R-TCGATGTACTGTCACTTAATGATG);   
plsR2  (F-AATTACAACGCCTCAAGCTG) 
(RGCACCATGGATGATTACTTC);  
cna  (F-AAAATGACAAAAATGGCAAG) 
(R-CAGGTTTAGTTGGTGGTGTT) 
 
 
Bacterial adhesion to solid-phase fibrinogen 
Flat-bottom 96-well microtiter plates were coated with 10 !g/well human 
fibrinogen for 2 h at 37°C. To block unspecific binding sites, 100 !l of a 2% 
solution of bovine serum albumin (BSA) in PBS was added per well and 
incubated at 4°C overnight. After four washing steps with PBS-Tween (0.05%), a 
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suspension of 50 !l of bacteria, prepared as described above, corresponding to 
5 x 108 CFU was applied to each well. Control wells were supplied with sterile 
PBS. The plates were incubated for 2 h at 37°C with gentle shaking. After four 
washing steps, bound bacteria were stained with 100 !l of 0.5% crystal violet in 
70% methanol per well. After 15 min of incubation, the plates were rinsed with 
water until all excess stain was removed. Bound bacteria were detached with 
100 !l of 33% acetic acid per well and the absorbance was determined at 
590 nm in an ELISA reader. Control wells were considered as background levels.  
 
Clumping assay with soluble fibrinogen 
Strains were grown as described above. 50 !l aliquots corresponding to 5 x 108 
CFU were transferred to a 96-well microtiter plate (Beckton Dickinson) containing 
serial twofold dilutions of human fibrinogen (Endotell, Switzerland) in PBS 
starting with 10 !g/50!l. After shaking 2 h at room temperature, each well was 
controlled for visible clumps or clots by microcopy. The clumping titer of each 
strain was determined as the highest dilution factor of fibrinogen that still resulted 
in visible clumping of the bacteria. 
 
Isolation and preparation of human PMN 
Human blood was taken from voluntary healthy donors and collected in EDTA. 
PMN were isolated by dextran sedimentation and density gradient centrifugation 
on a discontinuous Percoll gradient with 53% and 67% Percoll in PBS as 
described previously (9). The interface between the two Percoll layers containing 
the PMN was collected and contaminating erythrocytes were removed by 
hypotonic lysis. Cell numbers were determined by Türk staining.  
 
Chemotaxis of PMN 
Human PMN and bacterial supernatants were prepared as described.  
Chemotaxis of human PMN was determined assessing their migration towards 
bacterial supernatants using a 48-well microchemotaxis chamber as previously 
described (21). The wells of the lower chamber were filled with 28 !l of bacterial 
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supernatants, N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP), synthetic 
medium, or HHG+Ca2+ in quadruplicates. A 3 !m pore size polyvinylpyrrolidone-
free polycarbonate filter membrane (Nucleopore, Sterico AG, Switzerland) was 
placed between lower and upper wells, which were filled with 45!l/well (2.5 x 106 
PMN/ml in Hanks Hepes with Ca2+ with Glucose). The mounted chambers were 
incubated 30 min at 37°C in 5% CO2 humidified air. After incubation, chambers 
were disassembled, the membrane fixed and stained with Wright-Giemsa (Diff 
Quick, Medion Diagnostics, Switzerland). The number of cells, which migrated 
through the filter-pores, was determined by microscope. Migration of PMN was 
expressed as the mean percentage of cells migrated per well. Six replicates per 
sample were counted.  
 
Killing of bacteria by human PMN 
Bacteria and human PMN were prepared as described above.  
Bacteria were co-cultured with human PMN in a 1:1 ratio of 5 x 106 CFU/ml: 
5 x 106 PMN/ml in D-PBS CaCl2
+, MgCl2
+ (GIBCO) enriched with 10% complete 
normal human serum. The samples were incubated at 37°C for 3 h under 
continuous rotation at 200 rpm. At time points 0’, 30’, 60’ and 180’ aliquots were 
sampled and diluted in dH2O (pH11) to lyse PMN; further dilutions were plated 
onto BHI agar plates to quantify surviving bacteria. Bacterial growth in the 
absence of PMN was determined as positive control.  
 
Apoptosis of human PMN by bacteria 
Human PMN were prepared as described above. Bacteria were co-cultured with 
human PMN in a 1:1 ratio of 5 x 106 CFU/ml: 5 x 106 PMN/ml in D-PBS CaCl2, 
MgCl2 (GIBCO) enriched with 10% complete normal human serum. The samples 
were incubated at 37°C for 6 h under continuous rotation at 200 rpm. Cells were 
sampled at time points 0’ and 360’, centrifuged and the pellet was resuspended 
in Hepes buffer containing the dyes Annexin V and 7AAD. After 15 min of 
incubation at room temperature, samples were acquired with the flow cytometer. 
For analysis, gates were set on live (double negative staining), apoptotic 
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(Annexin V+/7AAD-), late apoptotic/early necrotic (double positive staining) and 
necrotic (Annexin V-/7AAD+) cells.  
 
Animal models 
Mice were kept in specific-pathogen-free conditions in the Animal House of the 
Department of Research, University Hospital Basel. All experiments were 
performed according to Swiss veterinary law. 
 
Intravenous challenge 
Female 6-8 week old Balb/c mice were inoculated with 200 !l of a suspension 
containing 2.9 x 106 CFU of bacteria intravenously via the caudal vein. Control 
mice were injected with 200 !l of 0.9% NaCl. The mice were monitored for nine 
days. On day 1, 4 and 7 mice were euthanized by CO2 inhalation. Organs were 
taken out and used for further cell preparations.  
 
Intraperitoneal challenge 
Female 14-16 week old C57Bl/6 mice were intraperitoneally inoculated with 2 ml 
of filtered culture supernatants using 25-G needles. Control mice were injected 
with 2 ml culture medium. After 6 h, mice were euthanized by CO2 inhalation and 
6 ml of RPMI containing 10% FCS were injected into the peritoneal cavity. 
Exudates were collected with 23-G needles from the peritoneum and leukocyte 
numbers were quantified using a Coulter Counter (Coulter Electronics). 
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RESULTS 
To certify the clonal nature of the 10 MRSA isolates used in chapter I, MLST was 
complemented by multi-locus variable-number tandem repeat (VNTR) analysis 
(MLVA). In our study, a total of 9 primer pairs were selected to map repeat-
containing genes that are encoding potentially important pathogenicity and 
virulence factors of S. aureus (4, 5). Since strains used in this study were MRSA 
isolates, a primer pair was selected to confirm the presence of mecA. The 
multiplex PCR profiles of 10 MRSA isolates that were formerly characterized by 
MLST and spa typing (described in chapter II) were analyzed by using a 
micro-capillary electrophoresis device (BioAnalyzer). Numerical files were then 
imported in specifically developed software performing UPGMA clustering that 
revealed genetic distance far below a cut-off value of 0.2 confirming high clonal 
relatedness among the isolates (Fig.1).  
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Fig.1: MLVA dendrogram of MRSA ST8 isolates  
Dendogram based on the allelic profiles of 10 MRSA isolates compared to MW2 
strain as reference. Red lines show the position of PCR products after 
normalization of PCR profiles. 
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Adhesion of MRSA ST8 to human solid-phase fibrinogen and clumping in 
the presence of soluble fibrinogen  
We assessed the binding capacities of the 10 MRSA ST8 isolates to human 
solid-phase fibrinogen and the degree of clump formation in the presence of 
soluble fibrinogen and tested whether the variable fibrinogen binding or clumping 
capacity was related to virulence of these isolates in vivo (Fig. 2). 
The adhesion to fibrinogen among isolates was heterogeneous. A clfA/B-
deficient mutant, used as negative control, showed nearby no adhesion (striped 
white bars). Newman strain was used as a positive control and elicited adhesion 
(striped grey bars). A specific adhesion pattern, discriminating lethal (closed 
bars) or non-lethal (open bars) isolates was not detected (Fig. 2A).  
Clumping of the isolates in the presence of human soluble fibrinogen was very 
heterogeneous among the isolates. The clfA/B-deficient mutant showed no 
clumping at all, while the Newman strain had a high clumping titer (striped grey 
bars) (Fig. 2B). Strain 0291, which yielded a very low adhesion, was also 
impaired in its clumping ability. This relationship between adhesion and clumping 
ability was not observed for the other strains.  
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Fig. 2: Bacterial adhesion to human solid-phase fibrinogen and clumping in 
presence of soluble fibrinogen by 10 clonal MRSA isolates  
A) Bacterial adhesion to human solid-phase fibrinogen was assessed by OD at 
590nm. Median values of three independent experiments with quadruplicates per 
isolate are shown. B) Clumping of bacteria in the presence of soluble fibrinogen 
was determined by the clumping titer. Median values of five independent 
experiments are shown. Non-lethal (open bars) and lethal (closed bars) isolates. 
A clfA/B-deletion mutant (striped white bars) and Newman strain, strongly 
expressing ClfA/B (striped grey bars) were used as negative and positive 
controls respectively.  
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Chemotaxis of human PMN towards supernatants of MRSA ST8 isolates  
We studied the chemotactic capacity of bacterial supernatants of single lethal 
and non-lethal MRSA ST8 isolates. These supernatants were used non-dialyzed 
or dialyzed to eliminate small chemotactic molecules such as fMLP. Medium 
alone was used as negative control and induced 21% of PMN migration. PMN 
migration towards fMLP in medium was used as a positive control and induced 
73% of PMN migration (Fig. 3A). PMN migration towards non-dialyzed 
supernatants of bacterial overnight cultures was ranging from 12 to 36% (Fig. 3B, 
closed bars) and was less than PMN migration towards dialyzed supernatants of 
bacterial overnight cultures, which was ranging from 56 to 76% (Fig. 3B, open 
bars). Inhibition of PMN migration was observed in some strains when non-
dialyzed supernatants were compared to sole medium. However, the extent of 
migration among dialyzed and non-dialyzed supernatants could not be related to 
virulence of the isolates in the sepsis model.  
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Fig.3: Chemotaxis of human PMN towards bacterial supernatants of O.N 
cultures from 10 clonal MRSA isolates 
A) Percent PMN migration towards medium (grey bar) and fMLP (striped bar) 
B) Percent PMN migration towards non-dialyzed (closed bars) and dialyzed 
(open bars) supernatants of 10 MRSA ST8 O.N. cultures. Strain numbers: 0012, 
0141, and 0143 were non-lethal in the sepsis model. Median values of 5 
replicates from two independent experiments are shown.  
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Chemotaxis of leukocytes towards MRSA ST8 supernatants in a murine 
peritonitis model 
We were interested if the 10 MRSA ST8 isolates had a variable ability to attract 
leukocytes in vivo. Thus, we determined the number of leukocytes entering the 
peritoneum 6 h after injecting bacterial supernatants i.p.. We observed variable 
migration of leukocytes ranging from baseline levels of about 500 leukocytes/!l to 
maximum levels of about 2000 leukocytes/!l. Supernatants of lethal (closed bars) 
and non-lethal (open bars) strains behaved similarly in their capacity to induce 
leukocyte attraction (Fig. 4).  
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Fig. 3: Number of leukocytes/!l after intraperitoneal injection of bacterial 
supernatants from 10 clonal MRSA isolates 
Leukocyte numbers in peritoneal fluid were determined 6 hours after i.p. injection 
of 2 ml bacterial supernatants of lethal (closed bars) and non-lethal (open bars) 
strains. IMDM was used as negative control (grey bars). Median values of three 
mice per isolate of one experiment are shown. 
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Killing of MRSA ST8 isolates by human PMN 
We were interested if certain isolates of MRSA ST8 were more resistant to killing 
than others and if there was a possible relation between susceptibility to killing 
and virulence in the former described murine sepsis model.  
The multiplicity of infection (MOI) was ranging from 0.03-2 (bacteria): 1 (PMN). 
Susceptibility to killing by human PMN was very heterogeneous among the 10 
MRSA ST8 isolates, especially within the first 30 minutes (closed bars), where 
survival of bacteria ranged from 30 to 90%. After 60 minutes (striped bars), 
surviving bacteria ranged from 5 to 40%. After 180 minutes (open bars), killing 
was most efficient and not more than 3% of bacteria were detectable. Kinetics of 
killing was not related to virulence in the sepsis model (Fig. 5).  
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Fig. 5: Killing of 10 MRSA ST8 isolates by human PMN 
Percentage of surviving bacteria, which were lethal (0019, 0020, 0064, 0065, 
0234, 0291) and non-lethal (0012, 0141, 0143) in the murine sepsis model, was 
determined after 30 min  (closed bars), 60 min (striped bars), and 180 min (open 
bars) of co-culture of bacteria with human PMN. Results are from one experiment 
and therefore have to be considered as preliminary data. 
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Apoptosis of human PMN induced by 10 MRSA ST8 isolates  
To elucidate, if the variable virulence of the MRSA ST8 isolates was related to 
either enhanced or diminished capacity to induce apoptosis, we measured the 
percentage of apoptotic human PMN induced by these bacteria (Fig. 6). Under 
our experimental conditions, about 50% of the untreated PMN were undergoing 
spontaneous apoptosis, while cyclohexamide treatment, used as a positive 
control, yielded 60% of apoptotic cells after 6 h. The fraction of apoptotic PMN in 
the presence of bacteria ranged from 18 to 27% after 6 h. These results 
demonstrate clearly, that MRSA ST8 isolates decelerate apoptosis at least 2 fold, 
when compared to spontaneous apoptosis of untreated PMN. The percentage of 
apoptotic cells was similar for lethal and non-lethal isolates.  
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Fig. 6: Apoptosis of human PMN induced by MRSA ST8 isolates  
Percent apoptotis of PMN was induced similarly by both, lethal (0019, 0020, 
0064, 0065, 0342, 0234, 0291) and non-lethal (0012, 0141, 0143) isolates after 6 
hours of co-culture (open bars). Closed bars: 0 min; PMN in PBS served as 
negative, cyclohexamide-treated PMN as positive controls. 
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Cellular host response against lethal and non-lethal isolates during sepsis 
in liver and spleen of Balb/c mice  
As we were interested in the innate and adaptive immune response to lethal and 
non-lethal MRSA ST8 isolates, Balb/c mice were infected with a lethal and a non-
lethal isolate or injected with NaCl; 1, 4, and 7 days after infection the cellular 
response in liver and spleen was determined. CD4+- and CD8+- T cells, among 
them activated cells, thus CD4+CD69+- and CD8+/CD69+- T cells, as well as B 
cells, myeloid cells, and PMN were detected. In addition, TCR gamma-delta- (%&) 
T cells, among them activated cells, thus TCR %&+CD69+-T cells were determined 
in the spleen. Mean fluorescent intensity (MFI) was measured for activated T 
cells. Among myeloid cells, highly Mac1-expressing cells were regarded as DCs. 
The response on day 4 after infection was most striking for all cells in both 
organs (Fig. 7 + 8).  
In the liver, infection of mice with the lethal or non-lethal isolate did not change 
the percentage of CD4+-T cells compared to mock-treated mice. Nevertheless, 
the lethal isolate induced activation of 80% of CD4+-T cells already on day 4, as 
indicated by the up-regulation of CD69 (Fig. 7A). Mice infected with a lethal 
isolate, showed a strong decrease in the percentage of CD8+-T cells own to 5% 
on day 4. More than 50% of this 5%- population was activated, as indicated by 
the up-regulation of CD69 and the MFI of CD8+/CD69+-T cells was enhanced 
(Fig. 7B). The B cell fraction decreased more strongly, after infection with the 
lethal than with the non-lethal isolate. The infection with the lethal isolate induced 
a stronger increase of DCs, than infection with the non-lethal isolate when 
compared with cells of mock-treated mice. On day 4, both isolates induced a 
PMN infiltration into the liver, but the percentage of PMN among liver cells was 
higher for the lethal than for the non-lethal isolate (Fig. 7C).  
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Fig. 7 Cellular response towards infection detected in liver 
Response of T cells (A+B), B cells, myeloid cells, and PMN (C) NaCl injection 
(grey bars) and infection with a lethal (black bars) and a non-lethal (white bars) 
isolate in the liver of Balb/c mice on days 1, 4, and 7. A) CD4+-T cells, 
CD4+/CD69+-T cells and MFI of CD4+/CD69+-T cells. B) CD8+-T cells, 
CD8+/CD69+-T cells and MFI of CD8+/CD69+-T cells. C) B cells, myeloid cells, 
and PMN 
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In the spleen, similar results were obtained. Infection of mice with lethal or non-
lethal isolates did not change the total percentage of CD4+-T cells compared to 
mock-treated mice. Nevertheless, both isolates induced activation of 20% of 
CD4+-T cells on day 4 as indicated by the up-regulation of CD69 (Fig. 8A). The 
MFI for CD4+/CD69+- T cells of mice infected with the lethal isolate was 1.6 fold 
higher than of those infected with the non-lethal isolate (Fig. 8A). Both, lethal and 
non-lethal isolates induced a modest activation of CD8+-T cells on day 4 without 
a change in the proportion of CD8 T cells (Fig. 8B). The lethal isolate induced a 
strong decrease in %&+-T cell fraction on day 4. About 40% of the remaining %&+-T 
cell cells were activated as indicated by the up-regulation of CD69 (Fig. 8C). B 
cells of mice infected with bacteria showed a decrease on day 1 of infection 
compared to mock-treated mice. Both isolates induced an increase in the 
percentage of DCs on all days of infection, which was stronger for the lethal than 
non-lethal isolate on the days 4 and 7. Also on day 4 and 7, both isolates induced 
a PMN infiltration into the spleen, but the percentage PMN among spleen cells 
was higher for the lethal than for the non-lethal isolate (Fig. 8D). 
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Fig. 8 Cellular response towards infection detected in spleen 
Response of T cells (A+B+C), B cells, myeloid cells, and PMN (D) NaCl injection 
(grey bars) and infection with a lethal (black bars) and a non-lethal (white bars) 
isolate in the spleen of Balb/c mice on days 1, 4, and 7. A) CD4+-T cells, 
CD4+/CD69+-T cells and MFI of CD4+/CD69+-T cells. B) CD8+-T cells, 
CD8+/CD69+-T cells, and MFI of CD8+/CD69+-T cells. C) %&(GD)+-T cells, 
%&
+/CD69+-T cells and MFI of %&+/CD69+-T cells. D) B cells, myeloid cells, and 
PMN 
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Sepsis induced by MRSA ST8 isolates in Balb/c mice 
Due to their genetic background, certain mouse strains are more susceptible to 
infections than others (18). This is also the case for Balb/c mice, which are 
known to be more susceptible to bacterial infections than C57BL/6 mice. To 
assure that the observed pathogenicity of the different isolates was pathogen-
dependent in C57BL/6 mice (see chapter II) and not due to host related factors, 
we used 8 of 10 MRSA ST8 isolates (5 lethal and 3 non-lethal strains, as 
determined in C57BL/6 mice) to induce sepsis in Balb/c mice. Isolates, which 
were lethal in C57BL/6 mice showed a significantly higher mortality than non-
lethal isolates (P = 0.045), indicating the virulence pattern was similar in C57BL/6 
and Balb/c mice. As expected, Balb/c mice were more susceptible and even 
isolates, which were non-lethal in C57BL/6 mice, were lethal in Balb/c mice. 
However, the strains, which were lethal in C57BL/6 mice caused also 
significantly higher mortality in Balb/c mice (Fig. 9).  
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Figure 9. Percentage survival of Balb/c mice infected with MRSA ST8 
isolates 
Percentage survival of Balb/c mice infected with 5 isolates, which were lethal 
(closed circles) and 3 isolates, which were non-lethal (open circles) in C57BL/6 
mice. Median inoculum of 2.9x106 CFU/mouse. (Log-rank test in Kaplan-Meier 
analysis, P = 0.045). 3 mice were infected per isolate.  
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DISCUSSION 
 
The clonality of 10 MRSA isolates, which were characterized earlier by different 
molecular typing methods, was confirmed by MLVA. Despite their clonality, the 
10 MRSA isolates induced infection with a variable outcome in the murine sepsis 
model. To investigate the variability in outcome, we studied further pathogen 
phenotypes and evaluated differences in the host response towards these 
isolates.  
We studied first the adhesion and clumping capacity of our isolates, and did not 
find any relation between adhesion, clumping, and virulence in the murine sepsis 
model. Wann et al. demonstrated, that fibronectin-binding protein A (FnBPA) is 
able to bind fibrinogen via its N- terminal A domain and to compensate binding to 
soluble fibrinogen in the absence of ClfA/B (23). However, such an effect was not 
detectable in the clfA/B-deletion mutant, which showed very low adhesion, but no 
clumping. Since all isolates were harboring the fnbp and clf genes, the 
heterogeneous adhesion and clumping profile possibly depended on a 
heterogeneous adhesin protein expression.  
The ability to attract PMN was similar for all 10 MRSA supernatants. Dialyzed 
supernatants of overnight cultures enhanced chemotaxis of PMN up to 5 fold, 
suggesting that inhibitory molecules were eliminated by dialysis. Since a 
membrane pore size of 3.5 kDa was used for dialysis, the 14.1 kDa inhibitory 
protein CHIPS was still present in the dialyzed supernatants, and was therefore 
unlikely to play an important role; it is proposed that other secreted unknown 
molecules might inhibit PMN migration. In contrast to our results, Veldkamp et al. 
demonstrated that chemotaxis towards chemottractants like fMLP or C5a was 
strongly reduced after pre-incubation of PMN with dialyzed supernatants. But 
since this group used a 10 kDa pore membrane, it is possible that those 
inhibitory molecules were in the range from 3.5 to 10 kDa and therefore no more 
present in our supernatants (22). Due to its size of 60 kDa, also Eap was still 
present in our dialyzed supernatants. But since Eap is mainly inhibiting 
extravasation by interfering with receptors on endothelial and epithelial cells its 
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inhibitory function is negligible in our in vitro model, which was only containing 
PMN (7).  
Killing of bacteria by PMN was very heterogeneous within the first 30 min, but 
efficient for all isolates after 3 h. However, since the MOI was variable among the 
isolates, a clear interpretation of the results is difficult.  
Several groups showed that apoptosis was faster upon phagocytosis of S. 
aureus than spontaneous apoptosis and that it occurred already one hour after 
phagocytosis (12, 13). In contrast to these findings, we demonstrated, that 
apoptosis of PMN, when co-cultured with S. aureus, did not occur earlier than 6 
hours of incubation. Interestingly, bacteria did not accelerate but were 
decelerating the percentage of spontaneous PMN apoptosis.  
Compared to the well-studied innate immune response, little is known about 
adaptive immunity against S. aureus infections. Though, in our study, we 
detected differences in T and B cell responses to a lethal versus a non-lethal 
isolate.  
Since antigen-specific antibodies are not available in the early phase of infection, 
so called ‘natural antibodies’, which are secreted by B-1-B cells, might provide 
support to the defense against invaders (1). The decrease of B cell numbers 
observed in the spleen on day 1, might originate from B1-B cells migrating into 
the periphery and providing unspecific antibodies. Though, to confirm their 
presence a detection of their surface marker CD5 would be adequate.  
Our data of liver and spleen suggest that the infection with the lethal isolate 
induced a higher level of activation in CD4+-T cells than the infection with the 
non-lethal isolate. Considering that at day 4 adaptive immunity is not yet 
available it is possible that the activated CD4+-T cells are a particular subset of T 
cells such as NKT cells that do not require priming.  
Since variations in the response to the lethal and non-lethal isolates seem to 
contribute to the different outcome of infection, the role of different cell subsets 
will be investigated in more detail in a further study.  
In summary PMN chemotaxis, susceptibility to PMN killing, and apoptosis did not 
differ between lethal and non-lethal isolates, thus the innate host response did 
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not allow any conclusion on pathogen properties. Pilot measurements of the 
specific immune response point to a possible relation between the extent of T cell 
activation, the decrease in B cell number and lethal outcome. Further 
investigations are needed to relate and identify the bacterial antigens in the lethal 
strain with the strong T cell activation. 
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CONCLUDING REMARKS 
The main focus of this thesis is the problematic issue of antibiotic resistance in 
Staphylococcus aureus and its still unknown impact on virulence in localized and 
systemic infections. Since S. aureus per se is a pathogen that inherits a multitude 
of virulence factors enabling resistance to the host in multitudinous ways, the 
ability to evolve and acquire resistance mechanisms to different classes of 
antibiotics enhances its pathogenicity to a greater extent (6). The development of 
antibiotic resistance types in S. aureus that were addressed in this study, are 
illustrated in the following scheme: 
 
 
 
MRSA evolve from successful MSSA clones by the acquisition of SCCmec and 
bear the risk to become GISA upon exposure to glycopeptides or to become 
GRSA upon acquisition of vanA resistance from Enterococci (2, 4, 7).  
Due to the instability of Tn1547 in S. aureus, GRSA are a rare alternative to 
GISA. Though, this will change and will become a further serious issue once this 
mobile genetic element, carrying the van genes of Enterococci, will stably insert 
into the S. aureus genome. In contrast to GRSA, GISA is already frequently 
isolated from patients. In our first study, we could show that a development of the 
GISA phenotype is associated with a fitness cost of the pathogen. Thus, with our 
in vitro generated GISA strain, we confirmed several phenotypic alterations that 
were also observed in clinical isolates. In addition, we demonstrated that the 
acquisition of resistance was associated with a decreased expression of 
virulence genes. Interestingly, the advantage of this phenotype in the presence of 
glycopeptides turned into a disadvantage in the absence of glycopeptides, 
especially in an infected host. The absence of selective drug pressure and the 
presence of host factors resulted in a restoration of fitness and virulence at the 
cost of resistance. Compensatory mutations that were underlying the restored 
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fitness in our study mainly affected the resistance phenotype, indicating the next 
upcoming problem besides the emergence of GRSA: the emergence of fitter 
GISA variants that are able to compensate their fitness burden while keeping 
both their resistance and their virulence.  
In our second study, we were confronted with two pandemic MRSA clones that 
had already proven their success by their worldwide dissemination. Isolates of 
both clones were carrying SCCmec IV, which was shown not to impair the fitness 
of the bacterium as it was observed for its SCCmec I counterparts in vitro (3, 5). 
Moreover, the characteristic to accumulate further resistance and virulence 
determinants typical for strains carrying SCCmec II and III, forming them to highly 
virulent and multi-resistant pathogens, is absent in SCCmec IV strains. Thus, the 
high virulence of certain MRSA clones in our study, reflected in mouse mortality, 
and their success, reflected in their dissemination, is suggesting a crucial 
promoting role of their toxins and adhesins. Avid adhesive properties were 
already shown to promote epidemicity as shown for the epidemic Brazilian clone 
(1). However, the variable virulence among isolates of the same clone inheriting 
the same toxin and adhesin gene profile questions the role of toxins and 
adhesins as key players for pathogenicity. Despite the high discriminatory 
potential of the molecular typing methods that are used, the influence of host 
factors and drug treatment on the pathogen during an infection is unknown. 
Therefore, a characterization of these isolates by whole genome sequencing 
would be more adequate to detect differences, which are decisive for the 
different outcome in mortality and the different specific host response to lethal 
and non-lethal isolates, as it was described in the last chapter of this thesis. 
Identification of the presence or the absence of certain factors leading to the 
different stimulation of host cells, might also help to understand, why the host is 
on the one hand able, but on the other hand unable to cope with the pathogen.  
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